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Abstract
In a trial with a crossover design, participants receive a sequence of treatments over
two or more periods, with the outcome measured at the end of each period. In order
to estimate contrasts between direct treatment effects and between carryover treatment
effects, we model each observation as a linear combination of the effects of period,
participant, the direct effect of the current treatment, and, for all except the first period
observations, the carryover effect of the treatment in the preceding period.
In this thesis, we will consider some aspects of the design and use of crossover
experiments. Our focus will be on methods for construction and comparison of designs
which improve performance and are accessible to those researchers who need to use
crossover designs but who are not specialists in statistical methodology or the design of
experiments. In Chapter 2 we discuss the construction of balanced crossover designs. In
Chapter 3 we consider visual methods for determining the connectedness of block, row-
column, and a restricted class of crossover designs. In Chapter 4 we discuss participant
dropout in crossover designs, and introduce a new criterion for selecting a design that is
less likely to result in non-estimable treatment contrasts in the event of some participants
not completing the trial. In Chapter 5 we present a review of the use of crossover
designs in the scientific literature during a one-year period. In Chapter 6 we discuss the
relationship between the theory of crossover designs as described in the earlier chapters,
and the reality of the use of crossover designs as described in Chapter 5. We conclude by
discussing potential practical approaches for making some experimental design methods
more widely known and used by researchers who implement trials with crossover designs.
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Glossary
Notation First used Description
B page 13 block design
b page 13 number of blocks in a block design
D page 13 crossover design
dij page 13 [in a row-column design] treatment allocated to a plot in row
i and column j
dij page 13 [in a crossover design] treatment allocated in period i to
participant j
E page 26 set of edges
G page 26 graph
H(R) page 34 Ghosh graph of row-col design R
i page 13 block, row or period label (i = 0, . . . , r − 1)
j page 13 column or participant label (j = 0, . . . , s− 1)
k page 13 treatment label (k = 0, . . . , t− 1)
L(B) page 27 Levi graph of a block design B
m page 27 length of a path, walk or cycle in a graph
ni page 13 number of plots in block i for i = 1, . . . , b
R page 13 row-column design
r page 13 number of rows in a row-col design or number of periods in
a crossover design
Continued on next page
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Continued from previous page
Notation First used Description
s page 13 number of columns in a row-col design or number of
participants in a crossover design
t page 13 number of treatments in a design
T (B) page 31 treatment-concurrence graph of a block design B
V page 26 set of vertices
v page 26 vertex label
W (R) page 33 Wynn graph of 2-row row-col design R
yik page 13 [in a block design] response in a plot in block i to treatment
k
yijk page 13 [in a row-column design] response in a plot in row i and
column j to treatment k
yijk page 13 [in a crossover design] response in period i and participant
j to treatment k
τk page 13 effect of treatment k
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Chapter 1
Introduction
In this chapter we introduce crossover designs, two notable sources of information on
on which are the books by Jones and Kenward [21] and Senn [41]. We also define some
concepts and notation for other types of experimental designs: block designs and row-
column designs. Finally, we introduce some issues in experimental designs that will be
addressed in later chapters. Although crossover designs may be used in a wide range of
situations, for the purposes of describing and discussing the design we will assume the
application is that of a trial involving human participants.
1.1 Crossover designs
A crossover trial design, which may also be referred to as a changeover trial design, is an
experimental design in which each participant receives a sequence of two or more treat-
ments over the course of two or more treatment periods. This is in contrast to a parallel
group trial design, where each participant receives only one treatment for the duration
of the experiment. Each treatment period lasts for the same amount of time, and there
may be a washout period between treatment periods where the participants receive no
treatment. As each participant acts as their own control, the obvious advantage of
a crossover design is that it allows us to consider the within-participant variability in
responses to treatments. Another advantage is that as several observations are made
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on each subject, fewer subjects are required than in an equivalently powered parallel
group design. From the point of view of the trial participants, crossover designs may
be less appealing. This is because the total duration of a crossover design will generally
be greater than in an equivalent parallel group design, and the participants may expe-
rience greater inconvenience from receiving several types of treatment and undergoing
repeated assessments. However, some trial participants may welcome the opportunity
to receive different types of treatment.
It is only appropriate to use a crossover design for experiments where the condition
to be treated is relatively stable. The treatment must result in a reversible outcome, and
participants must return to their pre-treatment condition soon after treatment stops.
Examples of studies where a crossover trial might be appropriate are the treatment
of chronic conditions such as diabetes mellitus, arthritis, hypertension, asthma, and
hypercholesterolemia. An example of an inappropriate use of a crossover design would
be in the study of an infectious disease such as bacterial meningitis where the aim of
treatment is to cure the patient, and there is a risk of serious deteriation or death. As
well as medical applications, other areas where crossover designs are in common use
include sensory experiments [10] and animal feeding experiments [42].
The most straightforward situation in which a crossover design may be used is in
the comparison of two treatments. In this case, participants initially receive treatment
A or B in the first period, and then the alternative treatment in the second period.
This two-treatment two-period two-sequence crossover design may be referred to in the
literature as the AB/BA crossover design or the 2 × 2 crossover design. The designs
to be considered here are more complex, involving the comparison of at least three
treatments. An example of such a design, with three periods, three particpants and
three treatments which we will label {0, 1, 2}, is shown in Figure 1.1. In this design,
particpant 1 receives treatment 0 in the first period, treatment 1 in the second period
and treatment 2 in the third period, whereas the other two participants receive the
treatments in a different order.
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Participants
1 2 3
Periods 1 0 1 2
2 1 2 0
3 2 0 1
Figure 1.1: A crossover design for 3 treatments, 3 periods and 3 participants.
There are two types of treatment effect to consider in crossover designs: the direct
effect due to the treatment in the current period, and the carryover or residual effect
due to the treatment or treatments in preceding periods. Even with a washout period
between treatment applications, it is conceivable that the treatment in period i − 1
may impact on the response to the next treatment in period i. This effect may be
physical or psychological in nature, for example an amount of a drug remaining in the
body or an unpleasant experience of a prior treatment affecting the perception that a
participant has of the current treatment. The existence and nature of the carryover
effect is somewhat controversial, and how it should be quantified, and even whether
experimenters should aim to estimate it at all have been discussed in the literature [38,
39, 40, 36, 37].
Here we will assume the first-order or simple carryover model, which states that
the effect on the response of the treatment in the previous period is additive and lasts
for one period. This is the standard additive model for a crossover design [21, p.9],
as described here in Section 1.2. We will also surmise that estimating the carryover
effect of a treatment is indeed of interest to the investigator. The justification for this
is that all effects associated with a treatment or intervention should be estimated as
they may all be relevant when evaluating the overall comparison between treatments.
Additionally, it has been suggested that it is of importance to estimate the total effect
of a treatment, where the total effect is the sum of the direct effect and the carryover
effect [3]. The reason for this is that most treatments evaluated using a crossover design
are intended to be used on a long term basis, so the total effect may be in some cases
a more pragmatic measure of treatment effect in this context than the direct treatment
12
effect alone.
1.2 Notation for experimental designs
In this section, we introduce the notation that will be used to describe experimental
designs.
In a block design B with b blocks and t treatments, the experimental units are
divided up so that each unit appears in exactly one block, with each block containing
ni experimental units (i = 1, . . . , b). Each treatment therefore appears in one or more
blocks. The response of each experimental unit is modelled as a linear combination of
the treatment effect and the block effect, so the response yik of a unit in block i to
treatment k satisfies E(yik) = µ+ pii + τk , where µ is the overall mean, pii is the effect
of block i, and τk is the effect of treatment k.
In a row-column design R with r rows, s columns and t treatments, each experi-
mental unit appears in exactly two blocks: one row and one column. The response of
each experimental unit is modelled as a linear combination of the treatment effect, the
row effect, and the column effect. If the treatment allocated to the plot in row i and
column j is given by dij , then the response yij of a unit in row i and column j satisifes
E(yij) = µ+ pii + αj + τdij , where µ is the overall mean, pii is the effect of row i, αj is
the effect of column j, and τdij is the effect of treatment dij .
In a crossover design D with r periods, s participants, and t treatments, the treat-
ment allocated in the ith period to participant j is dij , where i = 0, 1, . . . r − 1 and
j = 0, 1 . . . , s− 1. Assuming the presence of direct and carryover treatment effects, the
response yij in period i of the jth participant satisfies E(yij) = µ+pii+αj+τdij +λdi−1,j ,
where µ is the overall mean, pii is the effect of period i, αj is the effect of the jth partic-
ipant, τdij is the direct effect of treatment dij , and λdi−1,j is the carryover effect of
treatment di−1,j (equal to zero when i = 1).
In all of these experimental designs, we do not aim to estimate the treatment effects
τ0, τ1, . . . , τt−1 (and, in the crossover design, λ0, λ1, . . . , λt−1). Instead, we estimate
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contrasts between treatment effects, for example τ1 − τ2 (and in the crossover design,
λ1 − λ2). So in the design in Figure 1.1, the contrast τ0 − τ1 may be estimated. If all
simple contrasts of the form τk − τl can be estimated in a design, then it is said to be
connected for direct treatment effects. Similarly, in the crossover design, if all simple
contrasts of the form λk − λl can be estimated, then the design is said to be connected
for carryover treatment effects.
1.3 Outline of thesis
In this thesis, we will consider some aspects of the design and use of crossover designs,
focussing in particular on methods to improve the performance of designs which are
accessible to those who may need to use crossover designs but who are not specialists
in statistical methodology or the design of experiments.
In Chapter 2, we define balanced crossover designs and explain how they can be
constructed. In Chapter 3, we consider visual methods for determining the connected-
ness of block designs, row-column designs, and a restricted class of crossover designs.
In Chapter 4, we discuss the problem of participant dropout in crossover designs, which
leads to missing observations. We review existing approaches to choosing designs so
that the impact of dropout is reduced (in particular, on the connectedness of the imple-
mented design), and introduce a new criteria for choosing designs which are less likely to
become disconnected due to participant dropout. In Chapter 5, we present a review of
the use of crossover designs in research published during a one year period. We survey
factors including the dimensions of the crossover designs, the models used, mention of
carryover effect, choice of design, and occurrence and impact of participant dropout. In
Chapter 6, we discuss the relationship between theoretical issues in crossover designs
encountered in Chapters 1 to 4, and the reality of the use of crossover designs in peer-
reviewed scientific publications (Chapter 5).
14
Chapter 2
Balanced designs
Balanced experimental designs are preferable to competing designs of the same dimen-
sions as they have increased efficiency according to various criteria. In this chapter
we give the properties required for a crossover design to be balanced, and review some
methods for constructing balanced crossover designs.
2.1 Balanced crossover designs
We define a balanced crossover design to be a design which is balanced for a first-order
carryover effect, as described by Williams [44].
Definition A crossover design D is balanced under the following conditions: (i) each
treatment appears the same number of times in each period; (ii) each participant receives
each treatment exactly once; (iii) each ordered pair of distinct treatments appears
consecutively in the same number of participants.
It follows that if the design D has t treatments, then the number of periods r and
the number of participants s are necessarily whole number multiples of t.
Hedayat and Asfarinejad [17] showed that within the class of crossover designs with
r periods, s participants, and t treatments, balanced designs are universally optimal
in the sense defined by Kiefer [22]. In particular, the sum of the variances of the
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contrasts between direct treatment effects are minimised, and the sum of the variances
of the contrasts between carryover treatment effects are minimised. It is therefore
important for the experimenter to choose a balanced design in order to obtain the most
efficient estimates of direct and residual treatment contrasts. We consider this further
in Section 2.2.
2.2 Universal Optimality
In this section, we consider Kiefer’s work on Universal Optimality, which gives certain
properties of the information matrix (C-matrix) of a design that are sufficient to demon-
strate that a design is optimum [22]. In order to demonstrate the symmetry that is
present in the C-matrix of a universally optimal design, we then derive the information
matrix of an example balanced crossover design.
2.2.1 Universal Optimality and the C-matrix
Kiefer’s important results on universal optimality and the C-matrix in [22] form the basis
for a large amount of the subsequent literature on design optimality. Other contributions
by Kiefer on optimality in experimental design have include work on optimal designs
under large-degree polynomial regression [23], and work on block designs and Latin
square designs which are optimal under an autocorrelation model [24].
Theorem 2.1 Let D∗ be a design in the class of competing designs D, with information
matrix CD∗ . Then D
∗ is universally optimal over D if the following two conditions are
satisfied:
1. The matrix CD∗ is symmetric.
2. The trace of CD∗ is maximised compared to all other designs in D.
Proof The proof is by Kiefer [22].
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0 1 2 3
1 2 3 0
3 0 1 2
2 3 0 1
Figure 2.1: The balanced crossover design D.
In the specific context of crossover designs under an additive model including period
effects, participant effects, direct treatment effects, and carryover treatment effects, this
result has been used by Hedayat and Asfarinejad [17] to demonstrate that crossover
designs which are balanced according to the definition in Section 2.1 are universally
optimal.
2.2.2 The C-matrix for a balanced crossover design
Consider the 4-treatment, 4-period, 4-participant design D shown in Figure 2.1, with
periods represented by rows and participants by columns. This is a balanced design as
each treatment appears exactly once in every period and in every participant, and each
treatment is followed once by every other treatment.
We construct the X-matrix of the design D, which describes how the blocks and
treatments are applied to each observation in the design, and use this to derive the
C-matrix. As D is balanced, and hence optimal, we will observe that the C-matrix is
symmetrical.
The design D consists of 16 observations, and the model for these includes an overall
mean, four period effects, four participant effects, four direct treatment effects, and four
carryover treatment effects. So the X-matrix for D is a 16 × 17 matrix which can be
partitioned in the following way
X = [116 XB XT ]
where
116 is a vector of length 16 with all entries equal to 1,
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XB is a 16×8 indicator matrix defined by the block effects (period and participant)
applied to each observation, and
XT is a 16×8 indicator matrix defined by the treatment effects (direct and carryover)
applied to each observation.
Then the components of the X-matrix are
XB =

1 0 0 0 1 0 0 0
0 1 0 0 1 0 0 0
0 0 1 0 1 0 0 0
0 0 0 1 1 0 0 0
1 0 0 0 0 1 0 0
0 1 0 0 0 1 0 0
0 0 1 0 0 1 0 0
0 0 0 1 0 1 0 0
1 0 0 0 0 0 1 0
0 1 0 0 0 0 1 0
0 0 1 0 0 0 1 0
0 0 0 1 0 0 1 0
1 0 0 0 0 0 0 1
0 1 0 0 0 0 0 1
0 0 1 0 0 0 0 1
0 0 0 1 0 0 0 1

,XT =

1 0 0 0 0 0 0 0
0 1 0 0 1 0 0 0
0 0 0 1 0 1 0 0
0 0 1 0 0 0 0 1
0 1 0 0 0 0 0 0
0 0 1 0 0 1 0 0
1 0 0 0 0 0 1 0
0 0 0 1 1 0 0 0
0 0 1 0 0 0 0 0
0 0 0 1 0 0 1 0
0 1 0 0 0 0 0 1
1 0 0 0 0 1 0 0
0 0 0 1 0 0 0 0
1 0 0 0 0 0 0 1
0 0 1 0 1 0 0 0
0 1 0 0 0 0 1 0

From [17], the C-matrix is given by
C = X′TXT −X′TXB(X′BXB)−X′BXT
The diagonal of matrix X′TXT gives the replication of the treatments, with off-
diagonal entries taking value zero. So as each treatment appears four times in D as a
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direct effect and three times as a carryover effect, then
X′TXT =

4 0 0 0 0 0 0 0
0 4 0 0 0 0 0 0
0 0 4 0 0 0 0 0
0 0 0 4 0 0 0 0
0 0 0 0 3 0 0 0
0 0 0 0 0 3 0 0
0 0 0 0 0 0 3 0
0 0 0 0 0 0 0 3

Similarly, the matrix X′BXB gives the number of times each of the periods and
participants appear in the design. So as each period has four observations, and each
participant contributes four observations, then
X′BXB =

4 0 0 0 0 0 0 0
0 4 0 0 0 0 0 0
0 0 4 0 0 0 0 0
0 0 0 4 0 0 0 0
0 0 0 0 4 0 0 0
0 0 0 0 0 4 0 0
0 0 0 0 0 0 4 0
0 0 0 0 0 0 0 4

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with
(X′BXB)
− =

1
4 0 0 0 0 0 0 0
0 14 0 0 0 0 0 0
0 0 14 0 0 0 0 0
0 0 0 14 0 0 0 0
0 0 0 0 14 0 0 0
0 0 0 0 0 14 0 0
0 0 0 0 0 0 14 0
0 0 0 0 0 0 0 14

The matrix X′TXB gives the number of times each treatment occurs in each period
or participant.
X′TXB =

1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
0 1 1 1 1 1 0 1
0 1 1 1 1 1 1 0
0 1 1 1 0 1 1 1
0 1 1 1 1 0 1 1

Similarly,
X′BXT =

1 1 1 1 0 0 0 0
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 0 1
1 1 1 1 1 1 1 0
1 1 1 1 0 1 1 1
1 1 1 1 1 0 1 1

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Then
X′TXB(X
′
BXB)
−X′BXT
=

1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
0 1 1 1 1 1 0 1
0 1 1 1 1 1 1 0
0 1 1 1 0 1 1 1
0 1 1 1 1 0 1 1


1
4 0 0 0 0 0 0 0
0 14 0 0 0 0 0 0
0 0 14 0 0 0 0 0
0 0 0 14 0 0 0 0
0 0 0 0 14 0 0 0
0 0 0 0 0 14 0 0
0 0 0 0 0 0 14 0
0 0 0 0 0 0 0 14


1 1 1 1 0 0 0 0
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 0 1
1 1 1 1 1 1 1 0
1 1 1 1 0 1 1 1
1 1 1 1 1 0 1 1

=

1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
1
4
0 14
1
4
1
4
1
4
1
4 0
1
4
0 14
1
4
1
4
1
4
1
4
1
4 0
0 14
1
4
1
4 0
1
4
1
4
1
4
0 14
1
4
1
4
1
4 0
1
4
1
4


1 1 1 1 0 0 0 0
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1
1 1 1 1 1 1 0 1
1 1 1 1 1 1 1 0
1 1 1 1 0 1 1 1
1 1 1 1 1 0 1 1

=

2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
3
2
3
2
3
2
3
2
3
2
5
4
5
4
5
4
3
2
3
2
3
2
3
2
5
4
3
2
5
4
5
4
3
2
3
2
3
2
3
2
5
4
5
4
3
2
5
4
3
2
3
2
3
2
3
2
5
4
5
4
5
4
3
2

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So
C = X′TXT −X′TXB(X′BXB)−X′BXT
=

4 0 0 0 0 0 0 0
0 4 0 0 0 0 0 0
0 0 4 0 0 0 0 0
0 0 0 4 0 0 0 0
0 0 0 0 3 0 0 0
0 0 0 0 0 3 0 0
0 0 0 0 0 0 3 0
0 0 0 0 0 0 0 3

−

2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
2 2 2 2 32
3
2
3
2
3
2
3
2
3
2
3
2
3
2
3
2
5
4
5
4
5
4
3
2
3
2
3
2
3
2
5
4
3
2
5
4
5
4
3
2
3
2
3
2
3
2
5
4
5
4
3
2
5
4
3
2
3
2
3
2
3
2
5
4
5
4
5
4
3
2

=

2 −2 −2 −2 −32 −32 −32 −32
−2 2 −2 −2 −32 −32 −32 −32
−2 −2 2 −2 −32 −32 −32 −32
−2 −2 −2 2 −32 −32 −32 −32
−32 −32 −32 −32 32 −54 −54 −54
−32 −32 −32 −32 −54 32 −54 −54
−32 −32 −32 −32 −54 −54 32 −54
−32 −32 −32 −32 −54 −54 −54 32

So the C-matrix for the design in Figure 2.1 is symmetrical, as expected for the
information matrix of a design which we know to be universally optimal.
2.3 Williams’ designs
Williams [44] described the construction of balanced crossover designs with r = t periods
and s = t participants for t even, and r = t periods and s = 2t participants for t odd.
Where the number of treatments t is even, the first participant is allocated the sequence
of treatments
0 1 t− 1 2 t− 2 3 t− 3 . . . t/2
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For the remaining t − 1 participants, the treatment sequences are found by adding 1
mod t, 2 mod t, . . . , t−1 mod t to the treatments in this initial sequence. The t treat-
ment sequences form a balanced crossover design with numbers of periods, participants
and treatments all equal to t. Alternative treatment sequences for the first participant
which are not of this form are also given by Williams, for example
0 2 1 4 5 3
for t = 6.
Where the number of treatments is odd, a pair of sequences for an initial two
participants are used. These may be of the general form
0 1 t− 1 2 t− 2 . . . (t− 1)/2 (t+ 1)/2
and
(t+ 1)/2 (t− 1)/2 . . . t− 1 2 t− 1 1 0
A further t − 1 treatment sequences are obtained from each of these by adding 1
mod t, 2 mod t, . . . , t − 1 mod t to the treatments as before. This results in a
total of 2t treatment sequences, which form a balanced crossover design with t periods,
2t participants, and t treatments.
The Latin squares that Williams constructed may also, depending on orientation, be
known as row- or column-complete Latin squares, and the treatment sequences allocated
to the initial participants in the constructions are now recognised as terraces [2]. The
formal construction of column-complete Latin squares using terraces is described in the
next section.
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2.4 Column-complete Latin squares
If the treatments labelled (0, 1, . . . , t − 1) were arranged in a Latin square of side t,
then each treatment would appear once in each row and once in each column. In a
column-complete Latin square, each ordered vertical pair of treatments appear the same
number of times throughout the square. Considering periods as rows and participants as
columns, it is clear that a balanced crossover design is a column-complete Latin square.
Here we consider a method of constructing column-complete Latin squares, and hence
balanced crossover designs. The designs that can be constructed using this method
include those given by Williams [44].
Bailey [2] introduces the term terrace and discusses the construction of quasi-complete
and complete Latin squares using terraces. Terraces can be found for many groups, but
we will consider only the cyclic groups Zm; that is, the integers modulo m under addi-
tion.
Definition Let a = (a1, . . . , am) be a sequence which is a permutation of the elements
{0, . . . ,m − 1} of Zm. The differences are given by the sequence b = (0, b2, . . . , bm),
where bi = ai − ai−1 mod m for i = 2, . . . ,m. Then a is a terrace for Zm if for each
x ∈ Zm (x 6= m2 ), either x occurs twice and −x does not occur, or −x occurs twice and
x does not occur, or x and −x both occur once in the sequence b. If m is even then m2
must also occur once in b.
Definition If the elements of b are distinct then a is a directed terrace for Zm.
For example, if m = 6 and a = (0, 1, 4, 2, 3, 5) then b = (0, 1, 3, 4, 1, 2) and so a is
an undirected terrace for Z6. If a = (0, 1, 5, 2, 4, 3) then b = (0, 1, 4, 3, 2, 5) and so a is
a directed terrace for Z6. Although the term is not used, from [44], we know that for
any m the sequence wm = (0, 1,m− 1, 2,m− 2, . . .) is a terrace for Zm, and for even m
it is a directed terrace.
Let t be even, let a be a directed terrace for Zt, and let ct be the sequence (0, 1, . . . , t−
1). Then using [2] we can construct a Latin square L(a, ct). The ith entry of a is ai and
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the jth entry of ct is j−1, so the (i, j)th entry of L(a, ct) is given by lij = ai+j−1 mod t.
We define a crossover design D(a) where the treatment sequences are the columns of
L(a, ct), so D(a) is a balanced crossover design with t treatments, t periods and t
participants. For example, w6 = (0, 1, 5, 2, 4, 3) is a directed terrace for Z6 so the design
D(w6) in Figure 2.2 is a balanced six-treatment six-period six-participant crossover
design.
If t is odd then we can use an undirected terrace a = (a1, . . . , at) and its inverse
−a = (−a1, . . . ,−at), where −ai mod t = t − ai mod t. We form two Latin squares
L(a, ct) and L(−a, ct). The 2t columns of the two Latin squares give us a balanced
t-treatment t-period 2t-participant crossover design which we denote by D(a,−a). For
example w5 = (0, 1, 4, 2, 3), −w5 = (0, 4, 1, 3, 2) and so the balanced five-treatment
five-period ten-subject crossover design D(w5,−w5) is as shown in Figure 2.3.
0 1 2 3 4 5
1 2 3 4 5 0
5 0 1 2 3 4
2 3 4 5 0 1
4 5 0 1 2 3
3 4 5 0 1 2
Figure 2.2: The design D(w6)
0 1 2 3 4 0 1 2 3 4
1 2 3 4 0 4 0 1 2 3
4 0 1 2 3 1 2 3 4 0
2 3 4 0 1 3 4 0 1 2
3 4 0 1 2 2 3 4 0 1
Figure 2.3: The design D(w5,−w5)
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Chapter 3
Visual representations of
experimental designs
A visual representation of an experimental design, such as a graph, can be a useful
way to express certain properties of the design, and to allow competing designs to be
compared and discussed. Here we focus on graphs derived from designs that allow
whether the design is connected or not to be determined by inspection of the graph. In
this chapter we consider a selection of graphs that represent experimental designs, and
introduce a new way of using a graph to represent a crossover design with two periods.
3.1 Some basic graph theory and terminology
The first three chapters of Wilson [45] provide an introduction to the fundamental
concepts of graph theory, on which some of the following definitions are based.
Definition A graph G consists of a set of vertices V and a set of edges E. An
edge joining vertices v1 and v2 (v1, v2 ∈ V ) is denoted by the unordered pair {v1, v2}.
Figure 3.1(a) shows a graph with V = {0, 1, 2, 3} and edges E = {{0, 1}, {1, 2}, {1, 3}, {2, 3}}.
Definition A directed graph is a graph in which a direction is applied to each edge.
An edge from v1 to v2 is expressed as an ordered pair (v1, v2). The graph in Figure 3.1(b)
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is a directed graph with edges E = {(1, 0), (1, 2), (2, 3)}.
Definition A walk in G is a finite sequence of edges in which all pairs of consecutive
edges share a vertex. So the sequence ({v0, v1}, {v1, v2}, {v2, v3}, . . . , {vm−1, vm}) is a
walk in G from v0 to vm, of length m edges. A path is a walk in which the inner vertices
{v1, . . . , vm−1} are distinct. A cycle is a path which starts and ends at the same vertex
and has at least one edge. An elementary cycle is a cycle in which no vertex appears
more than once in the path. Figure 3.1(c) shows a path between vertices 0 and 2 within
the graph shown in Figure 3.1(a).
Definition A graph is connected if there is a path from v1 to v2 for each pair of vertices
v1, v2. A graph is disconnected if it is not connected. The graph in Figure 3.1(d) is
disconnected as there is no path from vertices 0 or 3 to vertices 1 or 2.
Definition A disconnected graph G is the union of two or more connected graphs.
Each of these connected graphs is a component of G. The graph shown in Figure 3.1(d)
has two components.
Definition If a graph G is bipartite, then the vertex set V can be split into two disjoint
sets V ′ and V ′′ such that each edge of G is of the form {v′, v′′},where v′ ∈ V ′and v′′ ∈
V ′′. Figure 3.1(e) shows a bipartite graph with disjoint vertex sets labelled with squares
and circles.
3.2 The Levi graph for a block design
The bipartite graph known as the Levi graph or incidence graph was initially described
by Levi [25, p.5]. As in Section 1.2, block design B has r blocks, t treatments, and ni
plots in each block (i = 0, . . . , r − 1), and the response yik on a plot in block i under
treatment k is given by E(yik) = µ+βi + τk, where i = 0, . . . , r−1 and k = 0, . . . , t−1.
Definition Let L(B) be the Levi graph of block design B. Then L(B) is a bipartite
graph with a set of vertices corresponding to the blocks 0, . . . , r− 1 of B, and a second
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Figure 3.1: Some examples of graphs.
set of vertices corresponding to the treatments 0, . . . , t − 1 of B. If block i contains
treatment k, then L(B) has an edge {i, k}.
Example 3.1 Figure 3.2 shows the Levi graphs of block designs B1 and B2. The square
vertices in the upper part of each graph are the block vertices, and the circular vertices
in the lower part of each graph are the treatment vertices.
B1
Block 0 0 1 1 2 2
Treatment 0 1 0 2 2 3
Response y00 y01 y10 y12 y22 y23
B2
Block 0 0 1 1 2 2
Treatment 0 1 2 3 0 1
Response y00 y01 y12 y13 y20 y21
t t t t
  
0 1 2 3
0 1 2

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L(B1) L(B2)
Figure 3.2: Examples of Levi graphs.
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In Chapter 1 we defined a design to be connected if all elementary treatment
contrasts were estimable. The term connected was used in a different way by Bose [5],
who first defined a block and a treatment to be associated if the treatment lies within
the block, and then:
“Two treatments, two blocks or a treatment and a block, may be said to be
‘connected’ if it is possible to pass from one to the other by means of a chain
consisting alternately of blocks and treatments, such that any two members
of a chain are associated.”
It is clear that this definition is equivalent to the existence of a path between the two
corresponding vertices in the Levi graph, although Bose does not use the term graph
here. Bose goes on to define a design to be connected if every block or treatment is
connected to every other block or treatment, a definition which corresponds to the Levi
graph of the block design being connected.
Theorem 3.1 (i) A block design B is connected for treatments if and only if the
vertices in the Levi graph L(B) corresponding to treatments in B are connected; (ii) a
block design B is connected for blocks if and only if the vertices in the Levi graph L(B)
corresponding to blocks in B are connected; (iii) the Levi graph L(B) of a block design
B is connected if and only if B is connected for all treatment and block contrasts.
Proof The proof (Bose [5] and Chakrabarti [8]) shows that the following are equivalent:
a block design B is connected for treatment effects in the usual sense; the information
matrix of B has rank t − 1; and B is connected for treatment effects in the sense of
Bose [5]. Consequently B is connected for treatment effects in the usual sense if and
only if the treatment vertices in the Levi graph L(B) are connected, so (i) is true. As
blocks and treatments may be interchanged in B and L(B), (ii) and therefore (iii) is
true.
Furthermore, we may consider this in the following way. Let the Levi graph L(B)
be connected for treatments. Then for any pair of treatments k1, km in B there is a
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path in L(B) between those vertices which correspond to k1 and km. If k1 and km are in
the same block b1, then the path will consist of the edges {k1, b1} and {km, b1}. These
edges correspond to the observations in B of yb1,k1 and yb1,km . Let c1 be the linear
combination of observations from B given by
c1 = yb1,k1 − yb1,km
so then
E(c1) = E(yb1,k1)− E(yb1,km)
= (µ+ βb1 + τk1)− (µ+ βb1 + τkm)
= τk1 − τkm
and so the treatment contrast τk1 − τkm can be estimated by c1. However, if k1 and
km are not in the same block, then the path between the vertices k1 and km will pass
through intermediate treatment vertices k2, . . . , km−1 and intermediate block vertices
b1, . . . , bm−1. The path will then consist of pairs of edges {k1, b1} & {k2, b1}, {k2, b2}
& {k3, b2}, . . . , and {km−1, bm−1} & {km, bm−1}. These pairs of edges correspond to
observations yb1,k1 & yb1,k2 , yb2,k2 & yb2,k3 , . . . , and ybm−1,km−1 & ybm−1,km . So the linear
combinations of observations in B given by
cj = ybj ,kj − ybj ,kj+1
can be estimated, with
E(cj) = τkj − τkj+1
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for j = 1, . . . ,m− 1. The sum of all such cj encountered along the path from k1 to km
then given by
m∑
j=1
E(cj) =
m−1∑
j=1
(τkj − τkj+1)
= τk1 − τkm
Example 3.1 (revisited) To then illustrate the use of this relationship between a
block design and the corresponding Levi graph, we consider the designs B1 and B2 and
Levi graphs L(B1) and L(B2) in Example 3.1. All treatment contrasts are estimable in
block design B1: the elementary contrasts τ0 − τ1, τ0 − τ2 and τ2 − τ3 can be estimated
by τˆ0 − τˆ1 = y00 − y01, τˆ0 − τˆ2 = y10 − y12 and τˆ2 − τˆ3 = y22 − y23 respectively, and
the remaining contrast estimates τˆ0 − τˆ3, τˆ1 − τˆ2 and τˆ1 − τˆ3 are linear combinations
of these. However, block design B2 is not connected as the only estimable elementary
contrasts are τ0−τ1 and τ2−τ3. By inspection of the Levi graphs, it is clear that L(B1)
is connected but L(B2) is not. The two components of L(B2) partition the treatment
vertices into {0, 1} and {2, 3}, corresponding to the only estimable treatment contrasts
in B2: τ0 − τ1 and τ2 − τ3.
The use of the Levi graph to determine which elementary contrasts are estimable
is straightforward, as suggested in Example 3.1. If there is a path between treatment
vertices k and l in L(B), then the elementary contrast τk − τl is estimable in B.
3.3 The treatment-concurrence graph
The treatment-concurrence graph T (B) of a block design B is described by John and
Williams [20, p.22] and Bailey [1, p.82]. The vertices of T (B) are the treatments of B,
and {k, l} is an edge whenever treatments k and l are in the same block.
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Example 3.2 The graphs T (B1) and T (B2) in Figure 3.3 are the treatment-concurrence
graphs of the block designs in Figure 3.2.
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Figure 3.3: Examples of treatment-concurrence graphs.
As with the Levi graph, the treatment-concurrence graph can be used to determine
the connectedness of a block design.
Theorem 3.2 The treatment-concurrence graph of a block design is connected if and
only if the block design is connected.
Proof The treatment-concurrence graph T (B) may be constructed by removing the
block vertices from L(B). It is therefore clear that there is a path between vertices k
and l in T (B) if and only if there is a path between vertices k and l in L(B). Hence
T (B) is connected if and only if L(B) is connected, and so from Theorem 3.1, T (B) is
connected if and only if the block design B is connected. 
The graph T (B1) in Figure 3.3 is connected, but T (B2) is not. The left-hand and
right-hand components of T (B2) correspond to the estimable contrasts τ0 − τ1 and
τ2 − τ3 respectively in B2. It is straightforward to find from T (B) which elementary
contrasts are estimable in B: if there is a path between vertices k and l in T (B), then
the elementary contrast τk − τl is estimable in B.
3.4 Row-column designs with two rows
Let R be a row-column design with two rows, s columns, and t treatments. The response
yijk of the plot in row i and column j under treatment k is given by E(yijk) = µ+ pii +
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αj+τk, where i = 1, 2, j = 1, . . . , s and k = 1, . . . , t. Wynn [46] defines a directed graph
for such a design, which we will denote W (R). The graph W (R) has t vertices, which
correspond to the treatments of R. The s edges of W (R) are defined by the columns
of R, in that (k, l) is an edge if there is a column with treatment k in the first row and
treatment l in the second row.
Example 3.3 The examples that we consider here are from Wynn [46]. Figure 3.4
shows the row-column designsR1 andR2 which have 2 rows, 5 columns and 5 treatments,
and the graphs W (R1) and W (R2).
The graph W (R) can be used to determine whether a row-column design with two
rows is connected.
Theorem 3.3 A row-column design R with two rows is connected for treatment effects
if and only if the graph W (R) satisfies the following two conditions: (i) the underlying
undirected graph is connected; (ii) the directed graph W (R) contains at least one
elementary unbalanced cycle.
Proof As demonstrated by Wynn [46], using network flow theory.
In Figure 3.4, the design R1 is connected, and the design R2 is not. Both of the
graphs W (R1) and W (R2) are connected, satisfying condition (i), but only graph W (R1)
contains the elementary unbalanced cycle required to satisfy condition (ii). Those
elementary contrasts which are not estimable in a row-column design R with two rows
cannot be easily determined from the graph W (R). In Figure 3.4, the contrast τ1 − τ0
is not estimable in R2. This fact could not be derived from simple inspection of the
graph W (R2).
3.5 Row-column designs with more than two rows
The Wynn graph for row-column designs with two rows (Section 3.4) cannot be easily
extended to row-column designs with more than two rows. The method described by
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Figure 3.4: Examples of graphs of row-column designs with two rows.
Ghosh [11] for determining whether a general row-column design is connected is quite
different to the Wynn graph. Let R be a row-column design with r rows and s columns.
Let H(R) denote the graph described by Ghosh, and as in [11], we assume without
loss of generality that r ≤ s. The vertices of H(R) are not individual treatments,
but instead pairs of treatments. A column block is a pair of columns of R, in which r
ordered pairs of treatments appear. The graph H(R) is constructed by first considering
the s column blocks consisting of column numbers (1, 2), (1, 3), . . . , (1, s), (2, 3). The
vertices of H(R) are the ordered pairs of treatments appearing in these column blocks.
To construct the edges of H(R), an equivalence relation ∼ is defined on both the set
of treatments 1, 2, . . . , k and the set of treatment pairs. When applied to the set of
treatments, k1 ∼ k2 if k1 and k2 are connected: that is, if the treatment contrast τk1−τk2
is estimable in R. When applied to the set of treatment pairs, (k1, k2) ∼ (k3, k4) if the
pairs (k1, k2) and (k3, k4) are connected: that is, if the contrast (τk4 − τk3)− (τk2 − τk1)
is estimable in R. A pair of vertices {(k1, k2), (k3, k4)} is an edge if the treatment pairs
(k1, k2) and (k3, k4) are connected by a column block. Treatment pairs can either be
connected by a column block if they are in the same column block, or if they can be
shown to be connected using the properties of the relation ∼
Theorem 3.4 The graph H(R) is connected if and only if the design R is connected
in the usual sense.
34
Proof This is proved by Ghosh [11], using the equivalence classes defined by ∼.
This method may not be easy to use in practice as the graph is not as straightforward
to construct and inspect as the Levi, treatment-concurrence and Wynn graphs. The
number of vertices and edges increases rapidly with the dimensions of the design. For the
row-column design R with r rows and s columns, s pairs of columns of R are used to form
the column blocks required for constructing H(R). So the maximum number of unique
ordered pairs of treatments and therefore vertices in H(R) is equal to r× s. Using this
method to determine whether a design R is certainly disconnected may be particularly
difficult, as all vertex pairs across presumed separate components of H(R) would have
to be assessed to establish that there was no possibility that the corresponding vertex
pairs could actually be connected using the properties of the equivalence relation.
3.6 Crossover designs with two periods
Consider a crossover design D with t treatments, 2 periods, and s participants.
Theorem 3.5 A two-period crossover design with 2s observations under the model
(1.2) is equivalent to a block design with s observations.
Proof This was proven by Hedayat and Asfarinejad [18]. Let xj be the difference
between the period 2 and period 1 observations for a participant j, so xj = y2j − y1j .
Then we have
E(xj) = E(y2j)− E(y1j) (3.1)
= pi2 − pi1 + τd2j − τd1j + λd1j .
We let pi = pi2 − pi1 and βd1j = λd1j − τd1j , so we have
E(xj) = pi + βd1j + τd2j . (3.2)
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This is the model for a block design B defined by D. As all t treatments appear in
each period, then B has t blocks and t treatments. The block effects are βd1j (d1j =
0, . . . , t−1) and the treatment effects τd2j (d2j = 0, . . . , t−1). Let Cdir be the information
matrix for the direct treatment effects in D, and let CB be the information matrix for the
treatments in the block design B. Hedayat and Asfarinejad [18] show that CB = 2Cdir.

We use this relationship between a two-period crossover design and a block design
to define the graph GD of a two-period crossover design D. An example is shown in
Figure 3.5. The vertices of GD are arranged in a 2× t grid, with each row representing
a period and each column representing a treatment. We label the vertex representing
treatment k in period i by ki. Then for each participant in D we draw an edge in GD
joining the first and second period treatments. So GD has an edge (k1, l2) if and only
if there is a participant in D with treatment k in the first period and treatment l in
the second period. Now consider the block design B which is formed from the two-
period crossover design D. It is clear that the bipartite graph GB as described above is
identical to the graph GD.
Theorem 3.6 The two-period crossover design D is connected for direct and carryover
treatment contrasts if and only if the graph GD of D is connected.
Proof If D is connected, then all elementary contrasts τk−τl and λk−λl are estimable
in (1.2). So the estimators τˆk− τˆl and λˆk− λˆl can be expressed as linear combinations of
the observations from D. The expectations of these estimators will clearly not involve
the participant effects. Let c be a linear combination of the observations in the crossover
design D such that the expectation of c does not involve the participant effects. We will
show that c can be expressed as a linear combination of the observations in the block
design B. From (1.2),
c =
s∑
j=1
(ajy1j + bjy2j)
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where aj and bj are the coefficients for the observations on participant j in the first and
second periods respectively. Under the model (1.2),
E(c) =
s∑
j=1
[ajE(y1j) + bjE(y2j)]
=
s∑
j=1
[
aj(µ+ pi1 + αj + τd1j ) + bj(µ+ pi2 + αj + τd2j + λd1j )
]
=
s∑
j=1
[
aj(µ+ pi1 + τd1j ) + bj(µ+ pi2 + τd2j + λd1j )
]
+
s∑
j=1
(aj + bj)αj .
As E(c) does not involve the participant effects, then aj + bj = 0 for all j = 1, . . . , s.
We put aj = −bj to get
c =
s∑
j=1
bj(y2j − y1j) =
s∑
j=1
bjxj ,
which is a linear combination of observations in B.
So the estimators of the contrasts may each be expressed as a linear combination
of observations xj from the block design B. Hence we can estimate the elementary
treatment contrasts τk−τl in B, and as βk−βl = (λk−τk)−(λl−τl) = (λk−λl)−(τk−τl)
then we can estimate the elementary block contrasts. Now suppose B is connected.
Then all elementary contrasts τk−τl and βk−βl are estimable in (3.2). So the estimators
τˆk − τˆl and βˆk − βˆl can be expressed as linear combinations of the observations from
B. It is obvious from (3.1) that these estimators can then each be expressed as a linear
combination of observations from D. So we can estimate the elementary treatment
contrasts τk − τl in D, and as λk − λl = (βk + τk)− (βl + τl) = (βk − βl) + (τk − τl) then
we can estimate the elementary contrasts between carryover treatment effects.
As GD and GB are identical, then from Theorem 3.1, GD is connected if and only if
B is connected. As D is connected if and only if B is connected, then we can conclude
that the two-period crossover design D is connected for direct and carryover treatment
contrasts if and only if the graph GD of D is connected. 
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Figure 3.5: (a) The crossover design D, (b) the graph GD, and (c) the block design B.
We illustrate this in Example 3.4, with the two-period crossover design D shown in
Figure 3.5.
Example 3.4 Crossover design D in Figure 3.5 has two periods, four participants, and
three treatments {0, 1, 2}. The graph GD is also shown, as is the block design B that
we can derive from D. It is clear that the Levi graph of B is identical to the graph
GD. Evaluation of D using the method described by Godolphin [15] shows that D is
disconnected, with τ0 − τ1 the only estimable elementary contrast. By inspection, GD
is not connected.
The result of Theorem 3.6 gives a simple method of checking if a proposed two-period
crossover design is connected, and hence a simple method for checking if a proposed
crossover design is connected on the first two periods (Section 4.2).
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3.7 General crossover designs
The method described in the previous section cannot be easily extended to crossover
designs with more than two periods, as the method relies on the relationship between
a two-period crossover design and a block design. Although crossover designs are not
explicitly discussed, the methods presented by Butz [6] could potentially be applied to
crossover designs. The method presented by Butz can be used to construct a graph for
a design with any number of factors (block types and treatment types). However, the
method is difficult to apply and not as intuitive as some of the other graphical methods
discussed in this chapter. Theoretically, a crossover design can be considered as a 4-
factor design with certain restrictions on the factors. These restrictions arise because
the levels of the third and fourth factors (the direct and carryover treatment effects) are
linked: a direct treatment applied in period i defines the carryover treatment in period
i + 1. The complexity of Butz’s method means that this graph would not be easy to
construct or easy to use to determine whether a design is connected.
3.8 Other methods for determining connectedness
The original motivation for visual methods that can be used to determine design
connectedness, such as that developed by Ghosh [11], was the computational difficulty
of otherwise assessing a design. Generally, the information matrix (C-matrix) would
have to be calculated, which was time and resource intensive, particularly if the process
was to be repeated for various competing designs. Methods such as Ghosh’s [11] and
the non-graphical method presented by Park and Shah [33] although less straightfor-
ward than the Levi or treatment-concurrence graphs, allowed a design to be assessed
without the need to derive the information matrix. As computing facilities have become
faster and cheaper, these concerns are less of a priority, but the appeal of straightfor-
ward methods to assess experimental designs remains, particularly those which allow
the user to easily determine which treatment contrasts are and are not estimable. For
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example, a method for detecting disconnected designs which can be applied to block
designs, row-column designs and crossover designs with first-order carryover effects has
been described by Godolphin [15].
However, such methods do not seem to have been widely used: according to Web
of Science (accessed March 2015), Ghosh’s paper has only been cited twice, on both
occasions in papers also on methods to determine the connectedness of designs. As part
of the process of enabling experimenters to understand the concepts of good experimen-
tal design, there would be benefits to making such methods more widely known and
accessible to those who might use them in practice.
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Chapter 4
Dropout in crossover trials
Even the most carefully designed of experiments may not always proceed as planned.
Potential problems common to all trial designs include missing data and participant
non-compliance. In trials with a crossover design there is the further possibility of
participant dropout, where participants complete some but not all of their full allocated
sequence of treatments. A possible consequence of this is that some treatment contrasts
will be non-estimable, an outcome that means that trial resources have been wasted.
In this chapter we consider how crossover trials may be designed so that the impact of
potential participant dropout is minimized.
4.1 Participant dropout
If participant j drops out before the end of the ith period of a p-period crossover design,
they will only contribute the i − 1 observations y1j , . . . , yi−1j . Even with careful trial
management, the multiple treatment periods that participants are required to complete
may mean that some degree of participant dropout is inevitable in crossover designs.
Low, Lewis and Prescott [28] state that “experience suggests that a dropout rate of
between 5% and 10% is not uncommon and, in some areas, can be as high as 25%”.
The resulting implemented design may be disconnected, with some direct or carryover
treatment contrasts being non-estimable. In order to protect resources invested in the
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trial, it is therefore essential to select a design that is more likely to remain connected
than competing designs in the event of participant dropout. As well as considering
financial and material resources, there are clear ethical implications of using a trial
design that is more vulnerable to dropout. This is because participants will have been
certainly inconvenienced and possibly exposed to some degree of risk in a trial that
might need to be repeated in order to obtain the required treatment contrast estimates.
Block designs have been previously described as robust if they are unlikely to become
disconnected due to missing observations [12, 13, 14]. Other authors have used the
term robust slightly differently to describe experiemental designs which perform well
according to additional criteria when observations are missing [28, 43]. Here we will
focus on reducing the risk of crossover designs becoming disconnected due to dropout,
and describe such designs as protected against participant dropout.
A method for assessing the robustness of a crossover design to participant dropout
is described by Low et al. [28]. For a given design, they compare the numerous designs
that could be implemented following every possible pattern of dropout. Even for a small
design the number of possible implemented designs is large: for example, there are 106
possible implemented designs for a three-period design with two participants on each
of twelve distinct treatment sequences. The criteria used to compare the robustness
of competing designs are that the probability of implementing a disconnected design
must be acceptably small, and that implemented efficiency measures for estimating
both direct and carryover treatment contrasts must be close to those in the original
design. The use of Polya theory (further described in [27]) greatly reduces the amount
of computation required, but the resulting method remains computationally intensive.
Low et al.’s method is demonstrated by comparing the robustness to dropout of
two balanced four-treatment four-period designs, each with 16 participants. One design
consists of four copies of a four-participant design, and the other consists of two copies
of an eight-participant design. Although dropout may occur at any point, the authors
observe that participants are most likely to drop out in the final period. This, along
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with computational restrictions, leads to the assumption in their examples that dropout
occurs only in the last period of an experiment. Of the 625 possible implemented designs
from the four copies of the four-participant design, 113 are disconnected. In contrast to
this, no possible implemented designs from the two copies of the eight-participant design
are disconnected. With participant dropout, the two copies of the eight-participant
design were found to perform better under the A and MV optimality criteria for both
direct and carryover treatment effects. A second example with 24 participants compared
suitable numbers of copies of the four-participant and eight-participant designs with two
copies of a balanced 12-participant design. The two copies of the 12-participant design
outperform the other two designs, and so the authors recommend using this design if
dropout in the final period is considered to be a likely occurrence.
In contrast to the final period dropout from several participants considered by Low et
al. [28], Varghese et al. [43] consider t-treatment (and hence t-period) Williams designs
(Section 2.3) where the last t− 1 observations are lost from one participant. They find
that all of the implemented designs are connected for direct and carryover treatment
contrasts, and that the efficiencies of the implemented designs relative to the original
designs are high. Where the number of treatments is equal to 3 or 4, the authors
replicate the design twice as they observe that a single replicate Williams design was
not sufficiently robust to this pattern of participant dropout.
A procedure is described by Godolphin [15, 16] which allows the identification of
rank reducing observation sets: sets of observations which would, if missing, result in
a disconnected design. To illustrate the importance of evaluating the risk of a design
becoming disconnected due to lost observations, an example is given of a crossover
design that became disconnected due to participant dropout in the final period. The
design consists of two copies of a four-treatment Williams square. Four participants,
representing two whole treatment sequence groups, drop out before the end of the
final period. In the implemented design, no elementary contrasts between direct or
carryover treatment effects are estimable. Godolphin gives an alternative design for the
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eight participants consisting of two different Williams squares. The implemented design
remains connected even if up to seven participants drop out in the final period. Rank
reducing observation sets have also been obtained for designs where the number of trial
participants is necessarily small, for example if recruitment is difficult, as it may be if
a rare medical condition is under investigation [4].
4.2 Method to select designs protected against dropout
It is clear that the risk of participant dropout in a crossover trial will be higher in the
later periods of the design than in the earlier periods. Suppose, in an extreme example,
a design D with p periods is terminated at the end of the qth period (1 ≤ q ≤ p).
If all direct and carryover treatment contrasts are still estimable in the implemented
design, that is if the original design D is connected on the first q periods, then D is
protected against any dropout in the later p− q periods. We propose that to reduce the
risk of an implemented design being disconnected, a planned crossover design should
be connected on the first two periods. This means that any participant dropout during
the third or subsequent periods may increase the uncertainty around our estimates but
will not compromise the connectedness of the design.
In order to estimate carryover effects, the implemented design must have at least
two periods. So to maximize the number of periods during which D is protected against
dropout, we choose q = 2. It is not suggested that a two-period design should be the
aim in such a trial, but rather that choosing a design connected on the first two periods
provides the experimenter with a generous safety net to protect against a disconnected
design. The graphical method described in Section 3.6 can be used to determine whether
the first two periods of a given crossover design are connected. If D is a crossover design
with p ≥ 2 periods, we define the graph GD to be the graph of the first two periods of
D. So D is connected on the first two periods if and only if GD is connected. If D has t
treatments, then by definition GD has 2t vertices. For GD to be connected, there must
be at least 2t− 1 edges, corresponding to at least 2t− 1 participants in D. For D to be
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balanced, the number of participants must be a multiple of t. Consequently a balanced
t-treatment crossover design which is connected on the first two periods must have at
least 2t participants.
Insisting that a design be connected on the first two periods still allows for familiar
and commonly-used designs which are balanced for carryover effects. In Sections 4.3
and 4.4 we explain how the method described in Section 2.4 can be modified in order
to construct designs with these properties.
4.3 Construction of protected designs where t is odd
We first consider the construction of balanced designs protected against participant
dropout where there is an odd number t of treatments (t ≥ 3). From the construction
described in Section 2.4, we can use the terrace for Zt, wt = (0, 1, t− 1, 2, t− 2, . . .) and
its inverse −wt to form the balanced design D(wt,−wt) (Figure 4.1).
In D(wt,−wt), two participants receive treatment k in period 1, with one such
participant then receiving treatment k−1 in period 2, and the other receiving treatment
k + 1. Consequently in the bipartite graph GD(wt,−wt), vertex k1 is connected to the
vertices (k − 1)2 and (k + 1)2, so there is a path consisting of two edges that connects
k1 to (k + 2)1, via (k + 1)2, for all k ∈ {0, 1, . . . , t − 1}. If we start at 01 and proceed
along the edges of the graph according to this path, the sequence of period 1 vertices
that we visit is (01, 21, 41, . . . , (t−1)1, 11, 31, . . . , (t−2)1, 01) and the sequence of period
2 vertices that we visit is (12, 32, 52, . . . , (t−2)2, 02, 22, 42, . . . , (t−1)2). This is a path of
length 2t starting and finishing at vertex 01, passing through all other vertices exactly
once. Hence GD(wt,−wt) is a cycle of length 2t and so is connected. So, for t odd, the
balanced crossover design D(wt,−wt) is connected on the first two periods for t ≥ 3. For
example, the design D(w5,−w5) is shown in Figure 4.1(a) and the graph GD(w5,−w5)
in Figure 4.1(b). The graph GD(w5,−w5) is connected and so D(w5,−w5) is connected
on the first two periods.
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4.4 Construction of protected designs where t is even
We consider an even number of treatments (t ≥ 4), and aim to find balanced t-treatment
t-period designs with 2t periods. To construct these designs, we use the lifting method
for constructing directed terraces.
4.4.1 The lifting method for constructing directed terrces
Let a be a terrace for Zt (Section 2.4), where t ≥ 2 and t may be odd or even. It is possi-
ble to lift a to construct a directed terrace a′ for Z2t. The lifting method is described by
Ollis [32] for a general binary group G with |G| = 2t. The unique element z of order 2
in G generates a subgroup Λ(G), and a terrace for G/Λ(G) is then lifted to construct a
directed terrace for G. Here we describe the lifting method in terms of a terrace for Zt
being lifted to a directed terrace for Z2t. Our terrace for Zt, a = (0, a2, a3, . . . , at), has
differences given by the sequence b = (0, b2, b3, . . . , bt), where b2 = a2 and bi = ai−ai−1
for i = 3, . . . , t. We want to form a sequence b′ where b′ = (0, b′2, . . . , b′t, t,−b′t, . . . ,−b′2)
and b′i ∈ Z2t, i = 2, . . . , t. We choose values for the b′i by considering the following cases
for each bi, i = 2, . . . , t.
Case (I). If bi 6= t2 and bi = bj for some i, j ∈ {2, . . . , t}, i 6= j, then either b′i = bi
and b′j = t+ bj mod 2t or b
′
i = t+ bi mod 2t and b
′
j = bj .
Case (II). If bi 6= t2 and −bi = bj mod t for some i, j ∈ {2, . . . , t}, i 6= j, then
either b′i = bi and b
′
j = bj or b
′
i = t+ bi mod 2t and b
′
j = t+ bj mod 2t.
Case (III). If bi =
t
2 for some i ∈ {2, . . . , t}, then either b′i = bi or b′i = t + bi
mod 2t.
Forming a sequence a′ with differences given by b′ gives a directed terrace for Z2t.
46
(a
)
0
1
2
··
·
t
−
1
0
1
2
··
·
t
−
1
1
2
3
··
·
0
t
−
1
0
1
··
·
t
−
2
t
−
1
0
1
··
·
t
−
2
1
2
3
··
·
0
2
3
4
··
·
1
t
−
2
t
−
1
0
··
·
t
−
3
. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .
t+
1
2
··
·
··
·
··
·
t−
1
2
t−
1
2
··
·
··
·
··
·
t−
3
2
(b
)
t
t
t
t
t
t
t
t
t
t
0 2
1
2
2 2
3
2
4 2
0 1
1
1
2 1
3
1
4 1
 
 
 
 
















 
 
 
 
@
@
@
@
 
 
 
 
@
@
@
@
 
 
 
 
@
@
@
@
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
@
@
@
@
F
ig
u
re
4.
1:
(a
)
T
h
e
ge
n
er
al
b
al
an
ce
d
p
ro
te
ct
ed
d
es
ig
n
D
(w
t,
−w
t)
fo
r
t
o
d
d
,
an
d
(b
)
th
e
gr
a
p
h
G
D
(w
5
,−
w
5
).
47
Theorem 4.1 Let a be a terrace for Zt of the form (0, 2, . . .). Then we can use the
lifting method to construct a directed terrace a′ for Z2t of the form a′ = (0, 2, . . .).
Proof As a is of the form (0, 2, . . .), then the sequence of differences b is also of the
form (0, 2, . . .), so a2 = b2 = 2. When constructing the sequence b
′, regardless of which
of Case (I), Case (II) and Case (III) is satisfied by b2, we are able to choose b
′
2 such that
b′2 = b2 = 2. The sequence a′ constructed with differences given by b′ will therefore be
a directed terrace for Z2t of the form (0, 2, . . .). 
Example 4.1 If t = 6, then a = (0, 2, 3, 1, 4, 5) is an undirected terrace for Z6. The
differences are given by b = (0, b2, b3, b4, b5, b6) = (0, 2, 1, 4, 3, 1). As b2 = −b4 = 2, case
(II) applies. We can choose either b′2 = 2 and b′4 = 4 or b′2 = 8 and b′4 = 10. To construct
a terrace of the form (0, 2, . . .), we choose b′2 = 2 and b′4 = 4. Now b3 = b6 = 1, so
this is case (I) and we can choose b′3 = 1 and b′6 = 7. Finally, b5 = 3 =
t
2 so this is
case (III) and we can choose b′5 = 3. This gives b′ = (0, b′2, . . . , b′6, 6,−b′6, . . . ,−b′2) =
(0, 2, 1, 4, 3, 7, 6, 5, 9, 8, 11, 10). So the sequence with differences given by b′ is a′ =
(0, 2, 3, 7, 10, 5, 11, 4, 1, 9, 8, 6), which is a directed terrace for Z12.
4.4.2 Even values of t with t ≥ 6
For even values of t with t ≥ 6, the lifting method for constructing directed terraces
can be used to construct balanced crossover designs which are connected on the first
two periods.
Theorem 4.2 For all even t with t ≥ 6, there exists a directed terrace for Zt of the
form e = (0, 2, . . .).
Proof As t is even we can write t = 2km where k is an integer with k ≥ 1 and m
is odd with m ≥ 1. As m is odd, the map x 7→ 2x mod m is an automorphism of
Zm. From [2] we can multiply the elements of the terrace wm by 2 to get a terrace for
Zm. As 2wm = (0, 2,m− 2, 4, . . . ,m− 1, 1), then there exists an undirected terrace for
Zm of the form a = (0, 2, . . .). We can apply the lifting method to a and construct a
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directed terrace a′ for Z2m of the form a′ = (0, 2, . . .). Now suppose that we have a
directed terrace a = (0, 2, . . .) for Zt where t = 2km and k ≥ 1. Then we can apply the
lifting method to construct a directed terrace a′ = (0, 2, . . .) for Z2t. As 2t = 2k+1m,
this completes the induction on k.
Suppose m = 1, so t = 2k. First we consider k = 1 and k = 2, and note that no
directed terrace of the form (0, 2, . . .) exists for Z2 or Z4. Now we consider k = 3. By
exhaustive search, there are exactly 4 directed terraces for Z8 of the form (0, 2, . . .):
(0, 2, 1, 5, 3, 6, 7, 4), (0, 2, 3, 6, 5, 1, 7, 4), (0, 2, 5, 1, 7, 6, 3, 4) and (0, 2, 7, 6, 1, 5, 3, 4). We
can then use the same inductive argument as for the case m ≥ 3 to show that there
exists a directed terrace for Z2k of the form (0, 2, . . .) for all k ≥ 3. 
Example 4.2 Figure 4.2 shows D(w6, e), where e = (0, 2, 1, 4, 5, 3) is a directed terrace
for Z6, and the connected graph GD(w6,e). The terrace wt = (0, 1, t − 1, 2, . . .) is
a directed terrace for Zt, so D(wt) is a balanced t-treatment, t-period, t-participant
design. As e is also a directed terrace for Zt, then D(e) is also a balanced t-treatment
t-period t-participant design, and hence D(wt, e) is a balanced t-treatment t-period 2t-
participant design. In D(wt, e), each treatment k in period 1 is followed by treatments
k+1 and k+2 in period 2. So in the bipartite graph GD(wt,e), vertex k1 is connected to
the vertices (k+1)2 and (k+2)2, hence there is a path consisting of two edges from k1 to
(k+1)1 passing through (k+2)2. If we start at 01 and move along the edges of the graph
in this way, the sequence of period 1 vertices that we visit is (01, 11, 21, . . . , (t− 1)1, 01)
and the sequence of period 2 vertices that we visit is (22, 32, 42, . . . , 02, 12). This is a
path of length 2t starting and finishing at 01, passing through all other vertices exactly
once. Hence GD(wt,e) is a cycle of length 2t and so is connected.
4.4.3 The case t = 4
We now consider the special case t = 4. We cannot use the same construction as for all
even t ≥ 6 as no directed terrace of the form (0, 2, . . .) exists for Z4. The only possible
candidates are (0, 2, 1, 3) and (0, 2, 3, 1), which have sequences of differences (0, 2, 3, 2)
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and (0, 2, 1, 2) respectively, and so are not directed terraces for Z4. In fact we can show
that no design with the desired properties exists, and so for a balanced design with
t = p = 4 to be connected on the first two periods, at least n = 12 participants are
required.
Theorem 4.3 There does not exist a balanced design D with t = p = 4 and s = 8
which is connected on the first two periods.
Proof Suppose that such a design D exists. Then the graph GD of the first two periods
of D is a bipartite graph with 8 vertices and 8 edges. As D is balanced, each vertex
of GD has degree 2. As D is connected on the first two periods, it is clear that GD is
a cycle as shown in Figure 4.3(a). The unknown second period treatments are labelled
a, b, c, d. The first two periods of design D (Figure 4.3(b)) are unique up to permutation
of the treatment labels. As each treatment appears only once in each sequence of the
full design D, a 6= 0 and a 6= 1. So a ∈ {2, 3}, and similarly b ∈ {0, 3}, c ∈ {0, 1} and
d ∈ {1, 2}. Choosing a = 2 forces d = 1, c = 0, b = 3, which gives the possible first
two periods A of D in Figure 4.4. Choosing a = 3 forces b = 0, c = 1, d = 2, giving
the possible first two periods B of D in Figure 4.4. However, A is a permutation of B
formed by interchanging the treatments 0 and 2. So we need only consider A as the
first two periods of D.
We now consider the treatments in the remaining periods of D. Suppose the treat-
ment allocated to participant 1 in period 3 is d3,1 = 2. The ordered pair (1, 2) appears
in both participant 1 and in participant 3, so d3,8 = 0. This forces d4,8 = 2, so the
ordered pair (0, 2) appears in participants 2 and 8. So d3,7 = 1, which forces d4,7 = 2,
resulting in the ordered pair (1, 2) appearing more than twice in D.
Now suppose d3,1 = 3. If d3,2 = 1 then d4,2 = 3 and so the ordered pair (1, 3) would
appear in participants 1, 2 and 4. So we must instead have d3,2 = 3. Treatment 3 now
appears twice in period 3, forcing d3,6 = 1 and so d4,6 = 3. This results in the ordered
pair (1, 3) appearing in participants 1, 2 and 6. So the construction of D has failed, and
we conclude that such a design does not exist. 
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4.5 Performance and application of protected designs
We have shown that balanced t-treatment t-period 2t-participant crossover designs that
are connected on the first two periods exist for all odd t with t ≥ 3 and for all even t
with t ≥ 6. For odd t we have shown how to construct such designs using the terrace
wt = (0, 1, t−1, 2, t−2, . . .) and its inverse −wt = (0, t−1, 1, t−2, 2, . . .). For even t we
use the directed terrace wt to form a balanced t-period t-participant design, and we use
a directed terrace of the form (0, 2, . . .) to form another balanced t-period t-participant
design. Together these give a balanced t-period 2t-participant design which is connected
on the first two periods.
4.5.1 Simulation
In order to compare the performance of a protected design to that of a competing design
which is balanced but which is not connected on the first two periods, we consider a
simulation of participant dropout. Suppose a balanced design with t = p = 6 is required
for s = 12 participants. Figure 4.5 shows two possible choices: two copies of the six-
participant design D(w6), or a single copy of the 12-participant design D(w6, e) (using
e = (0, 2, 1, 4, 5, 3)).
The design D(w6, e) has been constructed to be connected after the first two periods,
and it can be shown that D(w6,w6) is connected only after the first three periods. This
suggests that choosing D(w6, e) would reduce the risk of a disconnected design. We
compared these designs using a simulation of dropout. For each participant, we assumed
the following probabilities of dropping out before the end of the given period, conditional
on being in the trial at the start of the period:
Period 1 2 3 4 5 6
P (dropout) 0.05 0.1 0.15 0.2 0.25 0.3
The simulation included 10000 runs for each of the two designs, and for each run
the process involved the following steps:
52
t
t
t
t
t
t
t
t
a
2
b 2
c 2
d
2
0
1
1
1
2 1
3
1
 
 
 
 
 
 
 
 
 
 
 
  P
P
P
P
P
P
P
P
P
P
P
P
0
0
1
1
2
2
3
3
d
a
a
b
b
c
c
d
(a
)
(b
)
F
ig
u
re
4.
3:
(a
)
T
h
e
fi
rs
t
tw
o
p
er
io
d
s
of
th
e
d
es
ig
n
D
an
d
(b
)
th
e
g
ra
p
h
G
D
.
0
0
1
1
2
2
3
3
1
2
2
3
3
0
0
1
0
0
1
1
2
2
3
3
2
3
3
0
0
1
1
2
A
B
F
ig
u
re
4.
4:
P
os
si
b
le
fi
rs
t
tw
o
p
er
io
d
s
of
d
es
ig
n
D
.
53
D
(w
6
,w
6
)
0
1
2
3
4
5
0
1
2
3
4
5
1
2
3
4
5
0
1
2
3
4
5
0
5
0
1
2
3
4
5
0
1
2
3
4
2
3
4
5
0
1
2
3
4
5
0
1
4
5
0
1
2
3
4
5
0
1
2
3
3
4
5
0
1
2
3
4
5
0
1
2
D
(w
6
,e
)
0
1
2
3
4
5
0
1
2
3
4
5
1
2
3
4
5
0
2
3
4
5
0
1
5
0
1
2
3
4
1
2
3
4
5
0
2
3
4
5
0
1
4
5
0
1
2
3
4
5
0
1
2
3
5
0
1
2
3
4
3
4
5
0
1
2
3
4
5
0
1
2
F
ig
u
re
4.
5:
C
om
p
et
in
g
d
es
ig
n
s
w
it
h
t
=
p
=
6
an
d
s
=
12
.
54
1. Begin with N = 12 participants. Independently, each have a 5% probability of
dropping out before the end of the 1st period. Observations from the 1st period
are available for the remaining N1 ≤ 12 participants.
2. The remaining N1 participants start the 2nd period. Independently, each have a
10% probability of dropping out before the end of the 2nd period. Observations
from the 2nd period are available for the remaining N2 ≤ N1 participants.
3. The remaining N2 participants start the 3rd period. Independently, each have a
15% probability of dropping out before the end of the 3rd period. Observations
from the 2nd period are available for the remaining N3 ≤ N2 participants.
4. The remaining N3 participants start the 4th period. Independently, each have a
20% probability of dropping out before the end of the 4th period. Observations
from the 4th period are available for the remaining N4 ≤ N3 participants.
5. The remaining N4 participants start the 5th period. Independently, each have a
25% probability of dropping out before the end of the 5th period. Observations
from the 5th period are available for the remaining N5 ≤ N4 participants.
6. The remaining N5 participants start the final period. Independently, each have a
30% probability of dropping out before the end of the final period. Observations
from the final period are available for the remaining N6 ≤ N5 participants.
After 10000 runs, 94 of the designs implemented from D(w6,w6) were disconnected,
and 15 of the designs implemented from D(w6, e) were disconnected. Although the
absolute probability of a design becoming disconnected is small, it is desirable to avoid
such an event, and the protected design offers a substantial reduction in risk.
4.5.2 Application
If the number of treatments t is odd (t ≥ 3), then we can construct a protected and
balanced design with 2t participants. Note that standard balanced designs for odd
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t require 2t participants, although for some larger values of t there exist balanced
designs with only t participants. The protected and balanced design D(wt,−wt) given
in Figure 4.1 can be used for all odd values of t (t ≥ 3).
If t is even (t ≥ 4), then some modification is needed to the designs most commonly
used. In Section 4.4 we saw that for t = 4 we need 12 participants for a balanced
design connected on the first two periods, and for even t ≥ 6 we need 2t participants.
It is currently common practice for experimenters to use several copies of a balanced
t-participant design if t is even. For example, [21, p.198] explicitly recommend using
a number of copies of a Williams square. As an alternative approach, we suggest that
the protected design is used but with fewer copies. So if 24 participants are available
and s = 4, then two copies of the protected and balanced four-treatment four-period
12-participant design should be used instead of six copies of the four-treatment four-
period four-participant Williams square. Note that this is the recommendation made
by Low et al. [28], using their robustness criteria and assuming dropout only in the final
period.
If t ≥ 6 then the protected and balanced 2t-participant design consists of two
balanced t-participant designs. Hence we do not necessarily need to have a number
of participants which is a multiple of 2t, as for balance we only need whole copies of
both of the individual t-participant designs. For example, if we have 18 participants
and t = 6 treatments, we could use the design D(w6,w6, e), which would be formed of
two copies of the left-hand square and one copy of the right-hand square of the design
shown in Figure 4.2.
From Section 4.4, if t is even and t ≥ 6 then we need the directed terrace w6 and a
directed terrace e for Zt of the form e = (0, 2, . . .). Some examples of terraces of this
form are given in Figure 4.6.
This is not an exhaustive list, and other examples for these values of t and for other
suitable t may be found using the described ‘lifting’ method.
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t e
6 (0, 2, 1, 4, 5, 3)
8 (0, 2, 1, 5, 3, 6, 7, 4)
10 (0, 2, 3, 9, 6, 1, 4, 8, 7, 5)
12 (0, 2, 3, 7, 10, 5, 11, 4, 1, 9, 8, 6)
Figure 4.6: Directed terraces e = (0, 2, . . .) for Zt when t is even
4.6 Alternative model and connectedness conditions
In this section, we discuss two modifications to the problem of selecting designs which are
connected on the first two periods, and which are balanced. In Section 4.6.1, we consider
removing the carryover effects from the model. In Section 4.6.2, we consider keeping
the carryover effects in the model, but requiring only that the direct treatment effects
are connected. Finally, in Section 4.6.3 we apply these results to the special case t = 4,
which under the original conditions of the problem requires 12 (i.e. 3t) participants for
a balanced design which is connected on the first two periods (Section 4.4.3), whereas
all other t ≥ 3 require only 2t participants.
4.6.1 Removing the carryover effect from the model
If the carryover effect is removed from the model in Section 1.2 for a crossover design
D, observation yij in period i and participant j will satisfy
E(yij) = µ+ pii + αj + τdij
and D may be considered as a row-column design with periods as rows and participants
as columns.
When determining the connectedness of the first two periods of D, we can use the
Wynn graph for determining the connectedness of row-column designs with two rows
(Section 3.4, [46]). For the crossover design D, this defines a directed graph W (D)
where each vertex represents a treatment and each edge (k, l) represents a participant
receiving treatment k in period 1 and treatment l in period 2. The connectedness of the
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first two periods of D can then be determined by inspecting W (D), as D is connected
on the first two periods if the underlying undirected graph of W (D) is connected, and
if W (D) contains an elementary unbalanced cycle (Theorem 3.3).
Theorem 4.4 If carryover effects are not included in the model, then for all t ≥ 3
a t-treatment, t-period, t-participant crossover design exists which is connected on the
first two periods, and which is universally optimal for the estimation of direct treatment
effects.
Proof For t ≥ 3, let the t-treatment, t-period, t-participant crossover design D be
described by the t × t Latin square of the form shown in Figure 4.7, where the entry
in the ith row and jth column is given by (i− 1) + (j − 1) mod t. As the model does
not include carryover effects, D may be considered as a row-column design, and so,
as a Latin square, is balanced and so universally optimal for the estimation of direct
treatment effects [22]. In order to determine whether D is connected on the first two
periods, we consider the Wynn graph W (D) of the first two periods of the design shown
in Figure 4.7. Each treatment k (k = 0, 1, 2, . . . , t− 1) appears exactly once in the first
period, and is followed by treatment k + 1 mod t in the second period. The directed
graph W (D) is then a cycle with t edges (0, 1), (1, 2), (2, 3), . . . , (t − 1, 0). As this is
connected and also an elementary unbalanced cycle, then W (D) satisfies the conditions
of Theorem 3.3. Consequently, D is connected on the first two periods under the model
which excludes carryover effects. 
0 1 2 . . . t− 1
1 2 3 . . . 0
2 3 4 . . . 1
...
...
...
...
t− 1 0 1 . . . t− 2
Figure 4.7: Design D of Theorem 4.4, a t× t Latin square with entry (i− 1) + (j − 1)
mod t in row i and column j.
For all t ≥ 3, removing carryover effects from the model therefore allows us to choose
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designs with only t participants, which satisfy our requirements (optimal, and connected
on the first two periods).
4.6.2 Removing the requirement for a design to be connected for
carryover effects
Now we consider the problem where carryover effects remain in the model, but connect-
edness is only required for the direct treatment effects.
Theorem 4.5 LetD be a balanced t-treatment, t-period, s-participant crossover design
which is connected for direct treatment effects on the first two periods. Then D is also
connected for carryover treatment effects on the first two periods.
Proof Let k and k′ be treatments in the crossover design D, with k 6= k′. As D is
a balanced design, then from the definition in Section 2.1, k and k′ both appear in
the first period, allocated to participants j and j′ respectively, and are followed in the
second period by treatments l and l′ respectively, such that k 6= l and k′ 6= l′. The
difference between the two observations from participant j receiving treatments k in
the first period and l in the second period satisfies
E(y2j − y1j) = (µ+ pi2 + αj + τl + λk)− (µ+ pi1 + αj + τk)
= (pi2 − pi1) + (τl − τk) + λk
Similarly, the difference between the two observations from participant j′ satisfies
E(y2j′ − y1j′) = (pi2 − pi1) + (τl′ − τk′) + λk′
So, subtracting this value for particpant j′ from the value for participant j gives
E[(y2j − y1j)− (y2j′ − y1j′)] = [(pi2 − pi1) + (τl − τk) + λk]− [(pi2 − pi1) + (τl′ − τk′) + λk′ ]
= (τl − τk)− (τl′ − τk′) + (λk − λk′)
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As the first two periods of D are connected for direct treatment effects, then τk− τl and
τk′ − τl′ are estimable. Therefore the elementary contrast λk − λk′ is also estimable in
the first two periods of D, and so the first two periods of D are connected for carryover
effects. 
For all t ≥ 3, keeping carryover effects in the model but removing the requirement
for carryover treatment contrasts to be estimable reduces to the original problem, as
in balanced designs connectedness for direct treatment effects on the first two periods
implies connectedness for carryover treatment effects on the first two periods.
4.6.3 Implications for the case t = 4
As the main results for this chapter do not apply for the case t = 4, it is of interest to
consider what results can be obtained with alternative model specifications or connect-
edness conditions. In Section 4.6.1 we showed that if carryover effects were removed
from the model, a balanced t-treatment t-period design connected on the first two peri-
ods can be found with only t participants for t ≥ 3. Such a design for t = 4 is shown in
Figure 4.8. Without carryover effects in the model, this design is balanced. Addition-
ally, the design is connected on the first two periods, as can be determined from the
Wynn graph in Figure 4.9.
0 1 2 3
1 2 3 0
2 3 4 1
3 0 1 2
Figure 4.8: A crossover design for t = 4.
t
t t
t
0
1 2
3
6
-
?
ﬀ
Figure 4.9: The Wynn graph for the first two periods of the design in Figure 4.8.
In Section 4.6.2 we considered the effect of keeping the carryover effects in the model,
but removing the requirement that the carryover treatment contrasts be estimable.
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However, in Theorem 4.5 we showed that if the design is balanced, and if the direct
treatment contrasts are estimable on the first two periods, then the carryover treat-
ment contrasts are necessarily also estimable on the first two periods. Consequently,
attempting to apply this adjusted criteria to the case t = 4 will not represent any real
change, and so 3t = 12 participants will still be required for a balanced design which is
connected on the first two periods.
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Chapter 5
Survey of crossover trials
reported in the general scientific
literature
5.1 Introduction
It is important to investigate how trials with crossover designs are implemented in
applied research, so that the nature of any translational gap between the theory of
design of experiments and the reality of the use of such designs can be better under-
stood. A previous review of the methodological aspects of crossover trials has been
performed, which focussed on reports of crossover trials published during December
2000 and indexed on PubMed [31]. That review included 116 papers reporting a total
of 127 crossover trials, of which 72% were trials involving only two treatments, and
of the AB/BA design. It was reported that although most (70%) of the trials either
included or discussed a washout period, carryover effects were only discussed in 29%
of cases. Overall, the review authors found that key methodological issues were often
absent in reports of crossover trials.
The review of the use of crossover designs that we have undertaken and describe in
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this chapter differs in scope to the review by Mills et al [31]. Firstly, as the crossover
designs of interest elsewhere in this thesis are those with three or more treatments, we
did not consider crossover trials involving two treatments. Secondly, as many trials
involving a crossover design are found outside of the field of biomedical research, we
searched for publications indexed in the general scientific database Web Of Science. We
considered papers published during the whole of 2009.
5.2 Methods
The Web Of Science abstract database was searched for the following terms in the title,
abstract or keywords: ((trial OR experiment) AND (crossover OR cross-). Restricting
the search to items published during 2009, 3165 abstracts were identified. When these
were restricted to articles only, and then to those published in English, 2554 abstracts
remained under consideration. Each of these abstracts was inspected in the Web Of
Science interface in order to determine whether the terms ’crossover’ or ’cross-’ were
used in the appropriate context. When abstracts are viewed in Web Of Science following
a search, the search terms in the abstract, title and keywords are highlighted: this allows
the context in which the search terms are used to be determined accurately (Figure 5.1).
Following this process, 1851 abstracts were judged to be unrelated to crossover trials and
so were disregarded, with 703 abstracts remaining under consideration. Each of these
abstracts was then considered in more detail, to establish whether the corresponding
article was eligible for inclusion in this review.
Of the 703 abstracts under close consideration, 82 were excluded as they were found
to not be crossover designs, and 463 were excluded as they described crossover trials
with only two treatments. The number of studies remaining at this point and for which
the full-length articles were to be considered was 158: details of these are given in the
review bibliography.
Data from the articles selected for inclusion was entered into a form in an Access
database (Figure 5.2). Information collected included basic information about the size
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of the trial (number of treatments, number of periods, number of sequences, number
of participants), the general research area, and information about the design of the
trial, the analysis, and whether concepts such as carryover or a washout period were
mentioned.
5.3 Results
5.3.1 Characteristics of included studies
A total of 158 study articles were selected for inclusion on the basis of the two-stage
abstract screening process. Of these, 14 were found to be crossover trials with two
treatments, 14 were found to not be crossover trials, two reported on studies that were
not fully randomised, three were duplicate studies represented elsewhere in the sample,
and one article could not be obtained. These 34 studies were excluded, leaving a sample
of 124 study articles to be included (Figure 5.3). Some study articles reported on more
than one crossover design: in these cases, the first design mentioned in the article
was included. The characteristics of the included crossover trials are summarised in
Figures 5.4 and 5.5.
The included studies covered a wide range of research areas, including pain medi-
cation, pharmacology, nutrition, and livestock management. Most involved human
research participants, with 65 (52%) of trials involving healthy volunteers and 45 (36%)
involving patients.
Most of the included trials involved three treatments (66, 53%) or four treatments
(42, 34%) (Figure 5.4). The maximum number of treatments in a trial was nine. Most
trials took place over three periods (63, 51%) or four periods (41, 33%), and only
four trials had a number of periods that was not equal to the number of treatments
(Figure 5.5). The smallest trial involved three participants, and the largest involved
207 participants, with the median (interquartile range) of 20 (12 to 33) participants.
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Figure 5.2: Access database form used for capturing data on included studies.
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Figure 5.3: Flowchart showing studies selected for inclusion in review.
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Characteristic Number and % of trials
Washout included 83 67%
Carryover included in analysis 14 11%
mentioned only 14 11%
Sample size included details of calculation 31 25%
Participants
type healthy volunteers 65 52%
patients 45 36%
animals / livestock 13 10%
other 1 1%
number median 20
interquartile range 12 to 33
range 3 to 207
Figure 5.4: Characteristcs of the included crossover trials.
Figure 5.5: Dimensions of the included crossover trials. Shaded cells indicate equal
numbers of treatments and periods.
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5.3.2 Design
There was wide variation in how the study design was addressed, with the concept
of a design with different treatment sequences mentioned in 37 (30%) of studies. Few
reported details of specific crossover designs used, with most giving no more information
than that participants had been randomly assigned to treatments. However, Latin
squares were explicitly mentioned in 14 (11%) of studies, and several studies reported
the exact treatment sequences used.
5.3.3 Carryover effects
Most (83, 67%) of studies reported the use of a washout period between treatment
periods. Most did not address the issue of carryover or residual effects, although 14
(11%) accounted for carryover effects in the analysis, and a further 14 (11%) mentioned
the concept of carryover effects.
5.3.4 Sample size estimation
Details of the calculation performed to obtain the sample size estimation were reported
in 31 (25%) of studies, including power, significance level, effect size, and (in eight
studies) anticipated participant droput. Additionally, eight studies reported having
undertaken some form of sample size estimation, but did not report full details. Four
further studies had no mention of sample size estimation, but included remarks that
the sample size may have been too small.
5.3.5 Dropout
There was no report of participant dropout in 73 (59%) of trials. In the 51 studies
where dropout was reported, the median (interquartile range) proportion of participants
dropping out was 13% (8% to 20%). The largest reported dropout rate in a trial was
40%.
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5.4 Discussion
This exhaustive review of the use and reporting of crossover trials across a range of
scientific disciplines during a single year has provided a useful snapshot of the use of this
type of trial. We have found evidence that crossover trials with three or four treatments
are are actually used in practice, with occasional trials involving much larger numbers
of treatments. What is particularly clear from the studies considered here is that the
implementation of crossover designs in applied research goes far beyond the AB/BA
design which many may consider to be synonymous with the term ’crossover design’.
There is evidence that some quite complex crossover designs are being undertaken, with
large numbers of treatments.
As observed in the review by Mills et al. [31], reporting of information such as design
and the consideration of carryover effects is limited. However, in concordance with their
observations, we also found that the majority of researchers have considered washout
periods when implementing a trial with a crossover design.
Participant dropout is shown to be a concern, with one trial experiencing a 40%
dropout rate. Although most trials had no report of dropout, this does not necessarily
indicate an absence of dropout. While some studies provided full information about
the flow of their participants through the design, others reported only the number
who completed the trial, rather than also the number who were initially randomized.
Although no studies reported problems with estimating treatment contrasts due to
dropout, it is plausible that studies where there have been serious problems of this
nature may not be published.
This review only provides a limited snapshot of the use of crossover designs by
researchers, as many trials, particularly ones involving small numbers of particpants,
may not result in publication. It is also important to consider that what is published
on a study may not reflect exactly what the researchers wish to say about a study [9].
Possible reasons for this might include authors removing text to keep within the word
limit for a manuscript submission, or on acceptance a journal may request that some
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of the more technical detail in a paper is removed. Consequently researchers may
have considered issues such as choosing a balanced design, and carryover effect, but
the information has not been published. Another limitation of this review concerns
the search terms used. Restricting to abstracts where terms such as ”crossover” have
been used was a practical approach to the otherwise wide-ranging search, but it does
mean that all of the included studies are those which the researchers have explicitly
identified as being crossover designs. Other studies may have used designs that would
be recognisable as crossover designs, but may be referred to as something else if the
researchers were unfamiliar with this type of design. Consequently, in the sample of
studies captured from our search, researchers more familiar with crossover designs may
be overrepresented. It is of interest that in the review by Mills et al. [31], one third of
included studies did not use the term ”crossover” in either title or abstract.
In summary, although our sample may not be entirely representative of all crossover
trials actually being performed, it is clearly representative of crossover designs as reported
in the scientific literature. Crossover trials are used in many different disciplines, with
varying degrees of standards of reporting. Although a small proportion of researchers
appear to undertake crossover trials while considering carefully the relevant methodolog-
ical issues, another group of researchers seem to undertake potentially quite complex
trial designs with little or no reference to the supporting methodology. So that the
standard of such trials and their reporting might improve in the future, it is this group
that we will consider in Chapter 6.
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Chapter 6
Crossover design methodology
and crossover trials in practice
6.1 The translational gap
There is a large amount of research which is concerned with the design of crossover
trials, and, as we have seen in Chapter 5, there is a wide range of research situations in
which trials with a crossover design with three or more treatments are used. However,
what we have seen in Chapter 5 suggests that the relevant methodological issues may
not be considered for all such studies. This translational gap needs to be adressed, for
a number of reasons, and not only for the specific case of crossover trials. Firstly, the
methodology of a trial must be correct for the results to be considered valid. Secondly,
performing trials which are methodologically substandard may lead to problems such
as nonestimable treatment contrasts, or contrasts estimated with unnecessarily high
degrees of uncertainty. This can lead to wasted time and resources. Additionally, it
is important to consider the ethical implications of recruiting participants into a trial
which has been poorly designed and so has a higher risk of failure than if it had been
designed appropriately.
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6.2 Existing barriers to closing the gap
There are a number of issues that may be preventing the effective use of crossover design
methodology in applied research. One possibility is that often a statistician may not be
consulted about a trial until it has been completed and the results are to be analysed.
This enduring problem was acknowledged by R.A. Fisher in an address to the Indian
Statistical Congress in 1938:
“To call in the statistician after the experiment is done may be no more
than asking him to perform a postmortem examination: he may be able to
say what the experiment died of.”
The audience that methodology researchers have for their work should also be consid-
ered: they may write up their research primarily for other methodological researchers, so
that their work is not accessible to those who might apply it. It may be that methodol-
ogy researchers will make developments in their work in response to an applied problem
that they have perhaps been consulted on, but the communication between the method-
ology researcher and a specific applied researcher at that time may not be replicated
more generally. So a methodological development is communicated only to a number
of other methodology researchers by publication, and to one applied research by the
consultancy on the original problem.
It is likely that applied researchers will work within a particular research area, but
use a number of different techniques, tools and experimental designs. Consequently,
when faced with an unfamiliar study design, a lack of familiarity with the terms used in
describing aspects of the design may be a barrier to accessing the correct information
to be able to design the study appropriately. As an example of this, in the review of
crossover trials in Chapter 5, some studies that were not included had used the term
’crossover design’ to describe trials which were not crossover designs as generally defined
by statisticians.
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In the context of clinical trials for pharmaceutical interventions where the aim is to
gain approval from some agency such as the Food and Drug Administration in the US,
the trial design must adhere to very specific prescribed guidelines. As an additional
barrier, it could be argued that this encourages a conservative culture with respect to
trial design and statistical methodology, even in situations where the strict require-
ments for FDA approval do not apply. For example, pharmaceutical companies may
be reluctant to engage with unfamiliar methodological issues in their wider research, as
their concerns are primarily with meeting FDA approval in those situations where it is
relevant.
6.3 Possible solutions
We have identified potential three barriers to closing the gap between trial design
methodology and trial implementation by applied researchers: lack of communication
from methodology researchers to the applied researcher community; lack of familiarity
with specific design terms and issues making finding the right information more difficult;
and a conservative culture resistant to change. The third of these is the most difficult
to change, so we will consider potential solutions to barriers related to communication.
A possible approach is that methodology researchers could be encouraged, or required,
to make available plain language summaries for methodological papers so that applied
researchers can easily establish whether the methodology might be useful for them,
providing a route for future collaborations. Additionally, methodology researchers could
write up a more practical example-led version of any methodological paper for the clin-
ical or applied literatue.
Furthermore, information about appropriate experimental design could be made
available through a website which could act as a dynamic repository of designs. There
are currently a number of websites that aim to assist researchers with experimental
design choices, but many require the researcher to be familiar with the terminology
around the theory of experimental design. Examples are a website that includes a
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question-based selection key for choosing a design (http://dawg.utk.edu/choose.htm,
accessed March 2015), and a website for generating nested or crossed block designs
(http://www.expdesigns.co.uk, accessed March 2015). As one of the potential barriers
to accessing information may be unfamiliarity with the terminology, an appropriate
interactive graphical interface would allow the applied researcher to search the site by
characteristics of their design problem without requiring knowledge of the precise termi-
nology used. Additionally, as a potential application of some of the visual representa-
tions of designs presented here in Chapter 3 could be to further demystify experimental
design methodology, similar visual representations could be included on such a website.
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Chapter 7
Discussion
7.1 Conclusions
From Chapters 2 and 3 we have seen that there are methods by which designs can
be constructed, compared and discussed by non-specialists, for example by considering
a visual representation of the design. In Chapter 4 we introduced a straightforward
characteristic that a crossover design should have to reduce the risk of it becoming
disconnected due to participant dropout. Using designs which are connected on the
first two periods still allows the use of familiar balanced designs; just making a slightly
different, and still straightforward, choice of design will have no other impact than to
reduce the risk of a disconnected design. In Chapter 5 we saw that, despite there being
easily attainable benefits to good design choices, there was great variability in the imple-
mentation of crossover designs in applied research, with many studies apparently not
engaging with the concept of an experimental design at all beyond random assignment
to treatments. In Chapter 6 we discussed why that might be, and what might be done
to improve communication so that more applied researchers can benefit from the work
of methodological researchers.
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7.2 Further issues resulting from participant dropout
In this thesis, we have focussed on the problem of avoiding disconnected crossover
designs following participant dropout. However, there are other consequences which
may arise when planned observations are not available in a crossover trial, which we will
briefly discuss here. One possible consequence, which we have considered in Section 4.1,
is that the efficiencies of the estimators of the treatment contrasts may be markedly
reduced compared to the efficiencies in the planned design. Another important possible
consequence of data being missing is that, due to the reasons for the data being missing,
the resulting estimates may be biased.
Various analysis approaches may be used in the presence of missing data, the appro-
priateness of which vary according to the assumed underlying missingness mechanism
of the data. Missing data mechanisms are generally classified as missing completely at
random (MCAR), missing at random (MAR), or missing not at random (MNAR) [35,
26]. Under the MCAR assumption, the probability of an observation being missing
is independent of any observed or unobserved values. Under the MAR assumption,
the probability of an observation being missing depends only on the observed values.
Under the MNAR assumption, the probability of an observation being missing depends
on both observed and on unobserved values.
Where data are assumed to be MCAR, a complete case analysis would be appro-
priate: only those participants without any unobserved data would be included. If the
underlying missingness mechanism is MAR, a complete case analysis would induce bias.
However, other approaches such as multiple imputation could be used, where missing
values are predicted using existing values elsewhere in the dataset [7]. In the case of a
MNAR missingness mechanism, other approaches are needed in order to avoid bias.
A justification for an assumption of a MNAR missingness mechanism in a crossover
trial is that participants who have a poorer experience in one period may be more likely
to drop out in the next period [29]. Where the missingness mechanism is MNAR, an
inverse probability weighting approach can be used to avoid bias [34]. This method has
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been applied to a two-treatment two-period crossover trial with an AB/BA design [19],
where it was observed that there were practical difficulties involved in the use of the
method in this setting.
It has been argued that for a two-treatment crossover design, even if the missingness
mechanism is MNAR, a complete case analysis may in fact be the most appropriate
method [30]. The justification for this is that a complete case analysis compares the two
treatments within participants who are able to tolerate both treatments: in generalising
study results, this comparison would only be relevant to those who could tolerate both
treatments.
7.3 Future research
The survey of designs in Chapter 5 has provided a overview of what types of crossover
designs are being used and how the associated methodological issues are being addressed.
In order to better understand the gap between crossover design methodology and imple-
mentation in research, and to investigate how it can be addressed, it would be beneficial
to find out from applied researchers about their knowledge of experimental design, and
where they get their information from. One possible way to do this would be to identify
a number of published studies with crossover designs in a recent given time period,
perhaps using a similar approach to that in Chapter 5, and contact the study authors
with some survey questions on their experience of using a crossover design. This would
allow a wide range of views to be canvassed. Additionally, it could be determined
whether design details were in fact being considered by researchers undertaking exper-
iments, but not being included in resulting publications.
An alternative approach would be to undertake some qualitative interviews with a
smaller selection of applied researchers, which would be more resource-intensive, but
may allow for a deeper understanding of the issues involved, and better inform the
potential development of resources to improve researcher engagement with the method-
ology of crossover and other designs.
78
Bibliography
[1] R. A. Bailey. Association Schemes: Designed Experiments, Algebra and Combi-
natorics. Cambridge: Cambridge University Press, 2004.
[2] R. A. Bailey. “Quasi-complete Latin Squares: construction and randomization”.
In: Journal of the Royal Statistical Society, Series B 46.2 (1984), pp. 323–334.
[3] R. A. Bailey and P. Druilhet. “Optimality of neighbor-balanced designs for total
effects”. In: The Annals of Statistics 32.4 (2004), pp. 1650–1661.
[4] S.T. Bate, E.J. Godolphin, and J.D. Godolphin. “Choosing cross-over designs
when few subjects are available”. In: Computational Statistics and Data Analysis
52 (2008), pp. 1572–1586.
[5] R. C. Bose. “The design of experiments”. In: Proceedings of the 34th Indian
Science Congress, Part II (Presidential addresses), Section 2 (Statistics). 1947,
pp. 1–25.
[6] Lothar Butz. Connectivity in multi-factor designs: a combinatorial approach.
Berlin: Heldermann Verlag, 1982.
[7] J. Carpenter and M. Kenward. Multiple Imputation and its Application. Chich-
ester: Wiley, 2013.
[8] M. C. Chakrabarti. “On the C-matrix in design of experiments”. In: Journal of
the Indian Statistical Association 1 (1963), pp. 8–23.
79
[9] P. J. Devereaux et al. “An observational study found that authors of random-
ized controlled trials frequently use concealment of randomization and blinding,
despite the failure to report these methods”. In: Clinical Epidemiology 57 (2004),
pp. 1232–1236.
[10] C. Durier, H. Monod, and A. Bruetschy. “Design and analysis of factorial sensory
experiments with carry-over effects”. In: Food Quality and Preference 8.2 (1997),
pp. 141–149.
[11] S. Ghosh. “On a new graphical method of determining the connectedness in three
dimensional designs”. In: Sankhya 48.Series B, Pt. 2 (1986), pp. 207–215.
[12] S. Ghosh. “On robustness of designs against incomplete data”. In: Sankhya B
40.3–4 (1979), pp. 204–208.
[13] S. Ghosh. “Robustness of BIBD against the unavailability of data”. In: Journal
of Statistical Planning and Inference 6 (1982), pp. 29–32.
[14] S. Ghosh and S. B. Rao. “On a robustness property of PBIBD”. In: Journal of
Statistical Planning and Inference 8.3 (1983), pp. 355–363.
[15] J. D. Godolpin. “Simple pilot procedures for the avoidance of disconnected exper-
imental designs”. In: Journal of the Royal Statistical Society, Series C 53.1
(2004), pp. 133–147.
[16] J. D. Godolpin. “The specification of rank reducing observation sets in experi-
mental design”. In: Computational Statistics and Data Analysis 51 (2006), pp. 1862–
1874.
[17] A. Hedayat and K. Afsarinejad. “Repeated measurements designs, II”. In: The
Annals of Statistics 6.3 (1978), pp. 619–628.
[18] A. Hedayat and W. Zhao. “Optimal two-period repeated measurements designs”.
In: The Annals of Statistics 18.4 (1990), pp. 1805–1816.
[19] W. K. Ho et al. “Dropouts in the AB/BA crossover design”. In: Statistics in
Medicine 31 (2012), pp. 1675–1687.
80
[20] J. A. John and E. R. Williams. Cyclic and Computer Generated Designs. 2nd.
London: Chapman and Hall, 1995.
[21] Byron Jones and Michael G. Kenward. Design and Analysis of Cross-Over Trials,
Third Edition. London: Chapman and Hall, 2014.
[22] J. Kiefer. “Construction and optimality of generalized Youden designs”. In: A
Survey Of Statistical Designs and Linear Models (1975), pp. 333–353.
[23] J. Kiefer and W. J. Studden. “Optimal designs for large degree polynomial regres-
sion”. In: The Annals of Statistics 4.6 (1976), pp. 1113–1123.
[24] J. Kiefer and H. P. Wynn. “Optimum balanced block and Latin square designs
for correlated observations”. In: The Annals of Statistics 9.4 (1981), pp. 737–757.
[25] F. W. Levi. Finite geometrical systems (six public lectures delivered in February,
1940). Calcutta: University of Calcutta, 1942.
[26] R. J. A. Little and D. B. Rubin. Statistical analysis with missing data, Second
Edition. Hoboken: Wiley, 2002.
[27] J. L. Low, S. M. Lewis, and P. Prescott. “An application of Polya theory to
crossover designs with dropout”. In: Utilitas Mathematica 63 (2003), pp. 129–
142.
[28] J. L. Low, S. M. Lewis, and P. Prescott. “Assessing robustness of crossover
designs to subjects dropping out”. In: Statistics and Computing 9 (1999), pp. 219–
227.
[29] J. N. S. Matthews and R. Henderson. “Two-period, two-treatment crossover
designs subject to non-ignorable missing data”. In: Biostatistics 14 (2013), pp. 626–
638.
[30] J. N. S. Matthews et al. “Dropout in crossover and longitudinal studies: Is
complete case so bad?” In: Statistical Methods in Medical Research 23 (2014),
pp. 60–73.
81
[31] E. J. Mills et al. “Design, analysis, and presentation of crossover trials”. In: Trials
10 (2009), p. 27.
[32] M. A. Ollis. Sequenceable groups and related topics. The Electronic Journal of
Combinatorics. Dynamic Surveys (10). 2002.
[33] D. K. Park and K. R. Shah. “On connectedness of row-column designs”. In:
Communications in Statistics - Theory and Methods 24.1 (1995), pp. 87–96.
[34] J. M. Robins, A. Rotnitzky, and L. P. Zhao. “Analysis of Semiparametric Regres-
sion Models for Repeated Outcomes in the Presence of Missing Data”. In: Journal
of the American Statistical Association 90.429 (1995), pp. 106–121.
[35] D. B. Rubin. “Inference and missing data”. In: Biometrika 63.3 (1976), pp. 581–
592.
[36] S. Senn. “Consensus and controversy in pharmaceutical statistics”. In: The Statis-
tician 49.2 (2000), pp. 135–176.
[37] S. Senn. “Cross-over trials in drug development: theory and practice”. In: Journal
of Statistical Planning and Inference 96 (2001), pp. 29–40.
[38] S. J. Senn. “Cross-over trials, carry-over effects and the art of self-delusion”. In:
Statistics in Medicine 7 (1988), pp. 1099–1101.
[39] S. J. Senn. “Is the ’simple carry-over’ model useful?” In: Statistics in Medicine
11 (1992), pp. 715–726.
[40] S. Senn and D. Lambrou. “Robust and realistic approaches to carry-over”. In:
Statistics in Medicine 17 (1998), pp. 2849–2864.
[41] Stephen Senn. Cross-over trials in clinical research. Chichester: Wiley, 2002.
[42] E. D. Thomas et al. “Comparison of corn silage hybrids for yield, nutrient compo-
sition, in vitro digestibility, and milk yield by dairy cows”. In: Journal of Dairy
Science 84.10 (2001), pp. 2217–2226.
82
[43] C. Varghese, A. R. Rao, and V. K. Sharma. “Robustness of Williams square
change-over designs”. In: Metrika 55 (2002), pp. 198–208.
[44] E. J. Williams. “Experimental designs balanced for the estimation of residual
effects of treatments”. In: Australian Journal of Scientific Research, Series A 2
(1949), pp. 149–168.
[45] Robin. J. Wilson. Introduction to Graph Theory. 4th. Harlow: Prentice Hall,
1996.
[46] H. P. Wynn. “The combinatorial characterization of certain connected 2xJxK
three-way layouts”. In: Communications in Statistics - Theory and Methods
A6.10 (1977), pp. 945–953.
83
Chapter 5 review papers
[47] Mohammad Abdulwahab et al. “The efficacy of six local anesthetic formulations
used for posterior mandibular buccal infiltration anesthesia”. In: JOURNAL OF
THE AMERICAN DENTAL ASSOCIATION 140.8 (2009), 1018–1024.
[48] S. S. AbuMweis et al. “Plant sterol consumption frequency affects plasma lipid
levels and cholesterol kinetics in humans”. In: EUROPEAN JOURNAL OF
CLINICAL NUTRITION 63.6 (2009), 747–755.
[49] Kamayni Agarwal-Kozlowski, Ann-Christin Lange, and Helge Beck. “Contact-
free Infrared Thermography for Assessing Effects during Acupuncture: A Random-
ized, Single-blinded, Placebo-controlled Crossover Clinical Trial”. In: ANES-
THESIOLOGY 111.3 (2009), 632–639.
[50] J. Algorta et al. “Randomized, crossover, single-blind, placebo-controlled, human
pharmacology clinical trial with desoxypeganine, a new cholinesterase and selec-
tive MAO-A inhibitor: Multiple-dose pharmacokinetics”. In: INTERNATIONAL
JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 47.7
(2009), 483–490.
[51] Kosta Altis et al. “Analgesic efficacy of tramadol, pregabalin and ibuprofen in
menthol-evoked cold hyperalgesia”. In: PAIN 147.1-3 (2009), 116–121.
[52] Costas A. Anastasiou et al. “Sodium Replacement and Plasma Sodium Drop
During Exercise in the Heat When Fluid Intake Matches Fluid Loss”. In: JOUR-
NAL OF ATHLETIC TRAINING 44.2 (2009), 117–123.
84
[53] V. Arutchelvam et al. “Plasma glucose and hypoglycaemia following exercise in
people with Type 1 diabetes: a comparison of three basal insulins”. In: DIABETIC
MEDICINE 26.10 (2009), 1027–1032.
[54] Jo-An Atkinson et al. “A cluster randomized controlled cross-over bed net accept-
ability and preference trial in Solomon Islands: community participation in shap-
ing policy for malaria elimination”. In: MALARIA JOURNAL 8 (2009).
[55] Anna Axelin et al. “Oral Glucose and Parental Holding Preferable to Opioid
in Pain Management in Preterm Infants”. In: CLINICAL JOURNAL OF PAIN
25.2 (2009), 138–145.
[56] Sang-Cheol Bae et al. “Effects of Antioxidant Supplements Intervention on the
Level of Plasma Inflammatory Molecules and Disease Severity of Rheumatoid
Arthritis Patients”. In: JOURNAL OF THE AMERICAN COLLEGE OF NUTRI-
TION 28.1 (2009), 56–62.
[57] Olivier Bauwens et al. “24-hour bronchodilator efficacy of single doses of inda-
caterol in subjects with COPD: comparison with placebo and formoterol”. In:
CURRENT MEDICAL RESEARCH AND OPINION 25.2 (2009), 463–470.
[58] Eliseo Belda et al. “Anaesthetic and cardiorespiratory effects of romifidine/ketamine
combinations in cats”. In: VETERINARY ANAESTHESIA AND ANALGESIA
36.4 (2009), 299–307.
[59] Paulo S. Boggio et al. “Transcranial DC Stimulation Coupled With TENS for
the Treatment of Chronic Pain A Preliminary Study”. In: CLINICAL JOURNAL
OF PAIN 25.8 (2009), 691–695.
[60] Murielle Bortolotti et al. “High protein intake reduces intrahepatocellular lipid
deposition in humans”. In: AMERICAN JOURNAL OF CLINICAL NUTRI-
TION 90.4 (2009), 1002–1010.
[61] N. Bresolin, C. Zucca, and A. Pecori. “Efficacy and tolerability of eperisone in
patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial”.
85
In: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
13.5 (2009), 365–370.
[62] David R. Broom et al. “Influence of resistance and aerobic exercise on hunger,
circulating levels of acylated ghrelin, and peptide YY in healthy males”. In:
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE
AND COMPARATIVE PHYSIOLOGY 296.1 (2009), R29–R35.
[63] P. Casas-Agustench et al. “Acute effects of three high-fat meals with different fat
saturations on energy expenditure, substrate oxidation and satiety”. In: CLINI-
CAL NUTRITION 28.1 (2009), 39–45.
[64] Bridget A. Cassady et al. “Mastication of almonds: effects of lipid bioaccessibility,
appetite, and hormone response”. In: AMERICAN JOURNAL OF CLINICAL
NUTRITION 89.3 (2009), 794–800.
[65] Pablo Celnik et al. “Effects of Combined Peripheral Nerve Stimulation and Brain
Polarization on Performance of a Motor Sequence Task After Chronic Stroke”.
In: STROKE 40.5 (2009), 1764–1771.
[66] Dick C. Chan et al. “Regulatory Effects of Fenofibrate and Atorvastatin on
Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome”.
In: DIABETES CARE 32.11 (2009), 2111–2113.
[67] H. Peter Chase et al. “Pramlintide Lowered Glucose Excursions and Was Well-
Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized,
Single-Blind, Placebo-Controlled, Crossover Study”. In: JOURNAL OF PEDI-
ATRICS 155.3 (2009), 369–373.
[68] Dhruba J. Chatterjee et al. “Absence of QTc Prolongation in a Thorough QT
Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for
Treatment of Type 2 Diabetes”. In: JOURNAL OF CLINICAL PHARMACOL-
OGY 49.11 (2009), 1353–1362.
86
[69] Aurimery Gomes Chermont et al. “Skin-to-Skin Contact and/or Oral 25% Dextrose
for Procedural Pain Relief for Term Newborn Infants”. In: PEDIATRICS 124.6
(2009), E1101–E1107.
[70] Hugues Chevassus et al. “A fenugreek seed extract selectively reduces sponta-
neous fat consumption in healthy volunteers”. In: EUROPEAN JOURNAL OF
CLINICAL PHARMACOLOGY 65.12 (2009), 1175–1178.
[71] Sang-Heon Cho et al. “Pharmacokinetic, Tolerability, and Bioequivalence Compar-
ison of Three Different Intravenous Formulations of Recombinant Human Erythro-
poietin in Healthy Korean Adult Male Volunteers: An Open-Label, Randomized-
Sequence, Three-Treatment, Three-Way Crossover Study”. In: CLINICAL THER-
APEUTICS 31.5 (2009), 1046–1053.
[72] “Coadministration of Dabigatran Etexilate and Atorvastatin Assessment of Poten-
tial Impact on Pharmacokinetics and Pharmacodynamics”. In: AMERICAN JOUR-
NAL OF CARDIOVASCULAR DRUGS 9.1 (2009), 59–68.
[73] Heather M. Conklin et al. “Side Effects of Methylphenidate in Childhood Cancer
Survivors: A Randomized Placebo-Controlled Trial”. In: PEDIATRICS 124.1
(2009), 226–233.
[74] M. E. Corrigan et al. “Effect of corn processing method and corn wet distillers
grains plus solubles inclusion level in finishing steers”. In: JOURNAL OF ANIMAL
SCIENCE 87.10 (2009), 3351–3362.
[75] Rachel E. Cowan et al. “Impact of Surface Type, Wheelchair Weight, and Axle
Position on Wheelchair Propulsion by Novice Older Adults”. In: ARCHIVES OF
PHYSICAL MEDICINE AND REHABILITATION 90.7 (2009), 1076–1083.
[76] “Crushed sunflower, flax, or canola seeds in lactating dairy cow diets: Effects on
methane production, rumen fermentation, and milk production”. In: JOURNAL
OF DAIRY SCIENCE 92.5 (2009), 2118–2127.
87
[77] B. Dahlen et al. “Effect of formoterol with or without budesonide in repeated
low-dose allergen challenge”. In: EUROPEAN RESPIRATORY JOURNAL 33.4
(2009), 747–753.
[78] Christine Dalgard et al. “Supplementation with orange and blackcurrant juice,
but not vitamin E, improves inflammatory markers in patients with peripheral
arterial disease”. In: BRITISH JOURNAL OF NUTRITION 101.2 (2009), 263–
269.
[79] Stephen Daniels et al. “Celecoxib in the Treatment of Primary Dysmenorrhea:
Results From Two Randomized, Double-Blind, Active- and Placebo-Controlled,
Crossover Studies”. In: CLINICAL THERAPEUTICS 31.6 (2009), 1192–1208.
[80] Maria Leonarda De Rosa and Massimo Chiariello. “Candesartan Improves Maxi-
mal Exercise Capacity in Hypertensives: Results of a Randomized Placebo-
Controlled Crossover Trial”. In: JOURNAL OF CLINICAL HYPERTENSION
11.4 (2009), 192–200.
[81] Sara Dean, Andrea Braakhuis, and Carl Paton. “The Effects of EGCG on Fat
Oxidation and Endurance Performance in Male Cyclists”. In: INTERNATIONAL
JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM 19.6
(2009), 624–644.
[82] Mario Del Tacca et al. “Lack of pharmacokinetic bioequivalence between generic
and branded amoxicillin formulations. A post-marketing clinical study on healthy
volunteers”. In: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 68.1
(2009), 34–42.
[83] Aimee E. van Dijk et al. “Acute Effects of Decaffeinated Coffee and the Major
Coffee Components Chlorogenic Acid and Trigonelline on Glucose Tolerance”.
In: DIABETES CARE 32.6 (2009), 1023–1025.
88
[84] Enrique Dilone et al. “Rapid Oral Transmucosal Absorption of Sumatriptan, and
Pharmacodynamics in Acute Migraine”. In: HEADACHE 49.10 (2009), 1445–
1453.
[85] “Effects of nitrogen fertilization and cutting height on the forage yield and feeding
value of Eleusine indica in the dry season in Nepal”. In: WEED BIOLOGY AND
MANAGEMENT 9.2 (2009), 106–111.
[86] T. Enomoto et al. “Evaluation of the Efficacy and Safety of Olopatadine and
Fexofenadine Compared With Placebo in Japanese Cedar Pollinosis Using an
Environmental Exposure Unit”. In: JOURNAL OF INVESTIGATIONAL ALLER-
GOLOGY AND CLINICAL IMMUNOLOGY 19.4 (2009), 299–305.
[87] Andreas C. Eriksson et al. “Static platelet adhesion, flow cytometry and serum
TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopido-
grel in coronary artery disease: a randomised cross-over study”. In: JOURNAL
OF TRANSLATIONAL MEDICINE 7 (2009).
[88] Sima Fayyaz et al. “The cardiopulmonary effects of anesthetic induction with
isoflurane, ketamine-diazepam or propofol-diazepam in the hypovolemic dog”.
In: VETERINARY ANAESTHESIA AND ANALGESIA 36.2 (2009), 110–123.
[89] Andreas D. Flouris et al. “Acute and Short-term Effects of Secondhand Smoke
on Lung Function and Cytokine Production”. In: AMERICAN JOURNAL OF
RESPIRATORY AND CRITICAL CARE MEDICINE 179.11 (2009), 1029–
1033.
[90] Felice Francavilla et al. “Intrauterine insemination with or without mild ovar-
ian stimulation in couples with male subfertility due to oligo/astheno- and/or
teratozoospermia or antisperm antibodies: a prospective cross-over trial”. In:
FERTILITY AND STERILITY 92.3 (2009), 1009–1011.
89
[91] Kristin R. Freeland, G. Harvey Anderson, and Thomas M. S. Wolever. “Acute
effects of dietary fibre and glycaemic carbohydrate on appetite and food intake
in healthy males”. In: APPETITE 52.1 (2009), 58–64.
[92] Toshiaki Furubayashi et al. “Effects of Short-Term W-CDMA Mobile Phone Base
Station Exposure on Women With or Without Mobile Phone Related Symp-
toms”. In: BIOELECTROMAGNETICS 30.2 (2009), 100–113.
[93] Kuan Gandelman et al. “The Impact of Calories and Fat Content of Meals on
Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial”. In:
JOURNAL OF CLINICAL PSYCHIATRY 70.1 (2009), 58–62.
[94] Christopher D. Gardner, Lorraine M. Chatterjee, and Adrian A. Franke. “Effects
of isoflavone supplements vs. soy foods on blood concentrations of genistein and
daidzein in adults”. In: JOURNAL OF NUTRITIONAL BIOCHEMISTRY 20.3
(2009), 227–234.
[95] Ian Gilron et al. “Nortriptyline and gabapentin, alone and in combination for
neuropathic pain: a double-blind, randomised controlled crossover trial”. In:
LANCET 374.9697 (2009), 1252–1261.
[96] Amy Gonzales-Eguia et al. “Effects of nanocopper on copper availability and
nutrients digestibility, growth performance and serum traits of piglets”. In: LIVE-
STOCK SCIENCE 126.1-3 (2009), 122–129.
[97] Ravindra S. Goonetilleke and Errol R. Hoffmann. “Hand-skin temperature and
tracking performance”. In: INTERNATIONAL JOURNAL OF INDUSTRIAL
ERGONOMICS 39.4, Sp. Iss. SI (2009), 590–595.
[98] F. Grases et al. “Anticalculus effect of a triclosan mouthwash containing phytate:
a double-blind, randomized, three-period crossover trial”. In: JOURNAL OF
PERIODONTAL RESEARCH 44.5 (2009), 616–621.
90
[99] Davide Grassi et al. “Black tea consumption dose-dependently improves flow-
mediated dilation in healthy males”. In: JOURNAL OF HYPERTENSION 27.4
(2009), 774–781.
[100] Nicola Grossheinrich et al. “Theta Burst Stimulation of the Prefrontal Cortex:
Safety and Impact on Cognition, Mood, and Resting Electroencephalogram”. In:
BIOLOGICAL PSYCHIATRY 65.9 (2009), 778–784.
[101] P. M. Hellstrom et al. “Clinical trial: the glucagon-like peptide-1 analogue ROSE-
010 for management of acute pain in patients with irritable bowel syndrome: a
randomized, placebo-controlled, double-blind study”. In: ALIMENTARY PHAR-
MACOLOGY & THERAPEUTICS 29.2 (2009), 198–206.
[102] Kirsten F. Hilpert et al. “Effects of Dairy Products on Intracellular Calcium and
Blood Pressure in Adults with Essential Hypertension”. In: JOURNAL OF THE
AMERICAN COLLEGE OF NUTRITION 28.2 (2009), 142–149.
[103] Joanna Hlebowicz et al. “Effects of 1 and 3 g cinnamon on gastric emptying,
satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects”.
In: AMERICAN JOURNAL OF CLINICAL NUTRITION 89.3 (2009), 815–821.
[104] T. W. Ho et al. “Efficient assessment of neuropathic pain drugs in patients with
small fiber sensory neuropathies”. In: PAIN 141.1-2 (2009), 19–24.
[105] Marcelo Alcantara Holanda et al. “Influence of total face, facial and nasal masks
on short-term adverse effects during noninvasive ventilation”. In: JORNAL BRASILEIRO
DE PNEUMOLOGIA 35.2 (2009), 164–173.
[106] L. Holtshausen et al. “Feeding saponin-containing Yucca schidigera and Quillaja
saponaria to decrease enteric methane production in dairy cows”. In: JOURNAL
OF DAIRY SCIENCE 92.6 (2009), 2809–2821.
[107] Marcus Hompesch et al. “Pharmacokinetics and pharmacodynamics of insulin
lispro protamine suspension compared with insulin glargine and insulin detemir
91
in type 2 diabetes”. In: CURRENT MEDICAL RESEARCH AND OPINION
25.11 (2009), 2679–2687.
[108] Armin Imhof et al. “Effect of Drinking on Adiponectin in Healthy Men and
Women A randomized intervention study of water, ethanol, red wine, and beer
with or without alcohol”. In: DIABETES CARE 32.6 (2009), 1101–1103.
[109] Samir Jaber et al. “Adaptive Support and Pressure Support Ventilation Behavior
in Response to Increased Ventilatory Demand”. In: ANESTHESIOLOGY 110.3
(2009), 620–627.
[110] Laudan B. Jahromi et al. “Positive Effects of Methylphenidate on Social Commu-
nication and Self-Regulation in Children with Pervasive Developmental Disorders
and Hyperactivity”. In: JOURNAL OF AUTISM AND DEVELOPMENTAL
DISORDERS 39.3 (2009), 395–404.
[111] Emmanuele A. Jannini et al. “The ENDOTRIAL Study: A Spontaneous, Open-
Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil,
Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction”. In: JOUR-
NAL OF SEXUAL MEDICINE 6.9 (2009), 2547–2560.
[112] Louise Johnson, David B. Elliott, and John G. Buckley. “Effects of gaze strategy
on standing postural stability in older multifocal wearers”. In: CLINICAL AND
EXPERIMENTAL OPTOMETRY 92.1 (2009), 19–26.
[113] Carole Jubert et al. “Effects of Chlorophyll and Chlorophyllin on Low-Dose Afla-
toxin B-1 Pharmacokinetics in Human Volunteers”. In: CANCER PREVEN-
TION RESEARCH 2.12 (2009), 1015–1022.
[114] Gregory Kalogeropoulos et al. “The Effects of Short-Term Lens Wear and Eye
Rubbing on the Corneal Epithelium”. In: EYE & CONTACT LENS-SCIENCE
AND CLINICAL PRACTICE 35.5 (2009), 255–259.
92
[115] G. H. Kamimori et al. “Hormonal and Cardiovascular Response to Low-Intensity
Exercise With Atropine Administration”. In: MILITARY MEDICINE 174.3 (2009),
253–258.
[116] Yoshiko Kawakami et al. “Hypohomocysteinemic Effect of Cysteine Is Associated
with Increased Plasma Cysteine Concentration in Rats Fed Diets Low in Protein
and Methionine Levels”. In: JOURNAL OF NUTRITIONAL SCIENCE AND
VITAMINOLOGY 55.1 (2009), 66–74.
[117] Niina M. Kemppinen et al. “The Effect of Dividing Walls, a Tunnel, and Restricted
Feeding on Cardiovascular Responses to Cage Change and Gavage in Rats (Rattus
norvegicus)”. In: JOURNAL OF THE AMERICAN ASSOCIATION FOR LABO-
RATORY ANIMAL SCIENCE 48.2 (2009), 157–165.
[118] Martin Hartwig Kirschner et al. “Transdermal resorption of an ethanol- and
2-propanol-containing skin disinfectant”. In: LANGENBECKS ARCHIVES OF
SURGERY 394.1 (2009), 151–157.
[119] Janet Klein, William L. Nyhan, and Mark Kern. “The effects of alanine ingestion
on metabolic responses to exercise in cyclists”. In: AMINO ACIDS 37.4 (2009),
673–680.
[120] Michael Koenigs et al. “Bilateral frontal transcranial direct current stimulation:
Failure to replicate classic findings in healthy subjects”. In: CLINICAL NEURO-
PHYSIOLOGY 120.1 (2009), 80–84.
[121] Makiko Kokudai et al. “Effects of Statins on the Pharmacokinetics of Midazolam
in Healthy Volunteers”. In: JOURNAL OF CLINICAL PHARMACOLOGY 49.5
(2009), 568–573.
[122] Nicole Kotzailias et al. “Acute effects of hyperglycaemia on plasma concentration
of soluble P-setectin and von Willebrand Factor in healthy volunteers -a prospec-
tive randomised double blind controlled study”. In: THROMBOSIS RESEARCH
123.3 (2009), 452–459.
93
[123] Rossen Koytchev et al. “Influence of Acarbose on Blood Glucose and Breath
Hydrogen after Carbohydrate Load with Sucrose or Starch”. In: ARZNEIMITTEL-
FORSCHUNG-DRUG RESEARCH 59.11 (2009), 557–563.
[124] R. D. Lee et al. “Clinical trial: the effect and timing of food on the pharma-
cokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed
Release formulation of a proton pump inhibitor - evidence for dosing flexibility”.
In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS 29.8 (2009), 824–
833.
[125] S. Lennon et al. “Oseltamivir oral suspension and capsules are bioequivalent
for the active metabolite in healthy adult volunteers”. In: INTERNATIONAL
JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 47.8
(2009), 539–548.
[126] Helen J. Lightowler and C. Jeya K. Henry. “Glycemic response of mashed potato
containing high-viscocity hydroxypropylmethylcellulose”. In: NUTRITION RESEARCH
29.8 (2009), 551–557.
[127] Li-Chan Lin et al. “Using Acupressure and Montessori-Based Activities to Decrease
Agitation for Residents with Dementia: A Cross-Over Trial”. In: JOURNAL OF
THE AMERICAN GERIATRICS SOCIETY 57.6 (2009), 1022–1029.
[128] Dileep N. Lobo et al. “Gastric emptying of three liquid oral preoperative metabolic
preconditioning regimens measured by magnetic resonance imaging in healthy
adult volunteers: A randomised double-blind, crossover study”. In: CLINICAL
NUTRITION 28.6 (2009), 636–641.
[129] Horng-Yuan Lou et al. “Optimal dose regimens of esomeprazole for gastric acid
suppression with minimal influence of the CYP2C19 polymorphism”. In: EURO-
PEAN JOURNAL OF CLINICAL PHARMACOLOGY 65.1 (2009), 55–64.
94
[130] C. van Loveren et al. “Effect of Various Rinsing Protocols after Use of Amine
Fluoride/Stannous Fluoride Toothpaste on the Bacterial Composition of Dental
Plaque”. In: CARIES RESEARCH 43.6 (2009), 462–467.
[131] Heinz Lubenau et al. “Pharmacokinetic and Pharmacodynamic Profile of New
Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen (R)
Single-Blind, Randomized, Crossover Trial”. In: BIODRUGS 23.1 (2009), 43–51.
[132] Kevin C. Maki et al. “Postprandial metabolism with 1,3-diacylglycerol oil versus
equivalent intakes of long-chain and medium-chain triacylglycerol oils”. In: NUTRI-
TION 25.6 (2009), 627–633.
[133] Muhammad A. Malik et al. “A comparison of the Glidescope (R), Pentax AWS
(R), and Macintosh laryngoscopes when used by novice personnel: a manikin
study”. In: CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANA-
DIEN D ANESTHESIE 56.11 (2009), 802–811.
[134] Jeroen Maljaars et al. “Effect of fat saturation on satiety, hormone release, and
food intake”. In: AMERICAN JOURNAL OF CLINICAL NUTRITION 89.4
(2009), 1019–1024.
[135] Christopher P. F. Marinangeli, Amira N. Kassis, and Peter J. H. Jones. “Glycemic
Responses and Sensory Characteristics of Whole Yellow Pea Flour Added to
Novel Functional Foods”. In: JOURNAL OF FOOD SCIENCE 74.9 (2009),
S385–S389.
[136] Manuel Martinez-Aispuro et al. “Growth performance and plasma urea concen-
tration of growing pigs fed sorghum-soybean meal, low-protein diets”. In: VETERI-
NARIA MEXICO 40.1 (2009), 27–38.
[137] Antonio Marzo et al. “Pharmacokinetics of Isoxsuprine Hydrochloride Adminis-
tered Orally and Intramuscularly to Female Healthy Volunteers”. In: ARZNEIMITTEL-
FORSCHUNG-DRUG RESEARCH 59.9 (2009), 455–460.
95
[138] James J. McGough et al. “A Candidate Gene Analysis of Methylphenidate
Response in Attention-Deficit/Hyperactivity Disorder”. In: JOURNAL OF THE
AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY 48.12
(2009), 1155–1164.
[139] Alexander Medina-Remon et al. “Rapid Folin-Ciocalteu method using microtiter
96-well plate cartridges for solid phase extraction to assess urinary total pheno-
lic compounds, as a biomarker of total polyphenols intake”. In: ANALYTICA
CHIMICA ACTA 634.1 (2009), 54–60.
[140] Kenneth C. Mills et al. “A Clinical Trial Demonstration of a Web-Based Test for
Alcohol and Drug Effects”. In: JOURNAL OF STUDIES ON ALCOHOL AND
DRUGS 70.2 (2009), 308–313.
[141] Eliane C. Miotto et al. “Rehabilitation of executive dysfunction: A controlled
trial of an attention and problem solving treatment group”. In: NEUROPSY-
CHOLOGICAL REHABILITATION 19.4 (2009), 517–540.
[142] Eduardo Raposo Monteiro et al. “Comparative study on the sedative effects of
morphine, methadone, butorphanol or tramadol, in combination with acepro-
mazine, in dogs”. In: VETERINARY ANAESTHESIA AND ANALGESIA 36.1
(2009), 25–33.
[143] Simone Moore, Donovan Dwyer, and Glenn Arendts. “Laryngoscope illumina-
tion grade does not influence time to successful manikin intubation”. In: EMER-
GENCY MEDICINE AUSTRALASIA 21.2 (2009), 131–135.
[144] Lene S. Mortensen et al. “Differential effects of protein quality on postprandial
lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey,
casein, gluten, and cod protein”. In: AMERICAN JOURNAL OF CLINICAL
NUTRITION 90.1 (2009), 41–48.
96
[145] Sandi L. Navarro et al. “Cruciferous Vegetable Feeding Alters UGT1A1 Activ-
ity: Diet- and Genotype-Dependent Changes in Serum Bilirubin in a Controlled
Feeding Trial”. In: CANCER PREVENTION RESEARCH 2.4 (2009), 345–352.
[146] Sandi L. Navarro et al. “Modulation of Human Serum Glutathione S-Transferase
A1/2 Concentration by Cruciferous Vegetables in a Controlled Feeding Study Is
Influenced by GSTM1 and GSTT1 Genotypes”. In: CANCER EPIDEMIOLOGY
BIOMARKERS & PREVENTION 18.11 (2009), 2974–2978.
[147] L. Noehr-Jensen et al. “Escitalopram Is a Weak Inhibitor of the CYP2D6-
Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoal-
gesic Effect in Experimental Pain”. In: CLINICAL PHARMACOLOGY & THER-
APEUTICS 86.6 (2009), 626–633.
[148] J. A. van Noord et al. “The efficacy of tiotropium administered via Respimat
(R) Soft MistT (TM) Inhaler or HandiHaler (R) in COPD patients”. In: RESPI-
RATORY MEDICINE 103.1 (2009), 22–29.
[149] Havard Nygaard, Sissel Erland Tomten, and Arne Torbjorn Hostmark. “Slow
postmeal walking reduces postprandial glycemia in middle-aged women”. In:
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE
APPLIQUEE NUTRITION ET METABOLISME 34.6 (2009), 1087–1092.
[150] T. Pantalitschka et al. “Randomised crossover trial of four nasal respiratory
support systems for apnoea of prematurity in very low birthweight infants”.
In: ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL
EDITION 94.4 (2009), F245–F248.
[151] Shin-Ae Park et al. “Evaluation of the mydriatic effect of intracameral lido-
caine hydrochloride injection in eyes of clinically normal dogs”. In: AMERICAN
JOURNAL OF VETERINARY RESEARCH 70.12 (2009), 1521–1525.
[152] Amparo de la Pena et al. “AIR Insulin Capsules of Different Dose Strengths
May Be Combined to Yield Equivalent Pharmacokinetics and Glucodynamics”.
97
In: DIABETES TECHNOLOGY & THERAPEUTICS 11.Suppl. 2 (2009), S75–
S80.
[153] Frederik Persson et al. “Renal Effects of Aliskiren Compared With and in Combi-
nation With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and
Albuminuria”. In: DIABETES CARE 32.10 (2009), 1873–1879.
[154] Harry P. F. Peters et al. “No effect of added beta-glucan or of fructooligosaccha-
ride on appetite or energy intake”. In: AMERICAN JOURNAL OF CLINICAL
NUTRITION 89.1 (2009), 58–63.
[155] Sabrina Peterson et al. “CYP1A2, GSTM1, and GSTT1 Polymorphisms and
Diet Effects on CYP1A2 Activity in a Crossover Feeding Trial”. In: CANCER
EPIDEMIOLOGY BIOMARKERS & PREVENTION 18.11 (2009), 3118–3125.
[156] Thomas Rammsayer. “Effects of Pharmacologically Induced Dopamine-Receptor
Stimulation on Human Temporal Information Processing”. In: NEUROQUAN-
TOLOGY 7.1 (2009), 103–113.
[157] D. V. Ranawana et al. “Glycaemic index of some commercially available rice and
rice products in Great Britain”. In: INTERNATIONAL JOURNAL OF FOOD
SCIENCES AND NUTRITION 60.Suppl. 4 (2009), 99–110.
[158] Stewart J. Richmond et al. “Therapeutic effects of magnetic and copper bracelets
in osteoarthritis: A randomised placebo-controlled crossover trial”. In: COMPLE-
MENTARY THERAPIES IN MEDICINE 17.5-6 (2009), 249–256.
[159] N. E. Robinson et al. “Fluticasone Propionate Aerosol is More Effective for
Prevention than Treatment of Recurrent Airway Obstruction”. In: JOURNAL
OF VETERINARY INTERNAL MEDICINE 23.6 (2009), 1247–1253.
[160] Sergio Romero, Miguel A. Mananas, and Manel J. Barbanoj. “Influence of Ocular
Filtering in EEG Data on the Assessment of Drug-Induced Effects on the Brain”.
In: HUMAN BRAIN MAPPING 30.5 (2009), 1470–1480.
98
[161] P. Rosas-Ledesma et al. “Antimicrobial efficacy in vivo of a new formulation of
2-butanone peroxide in n-propanol: comparison with commercial products in a
cross-over trial”. In: JOURNAL OF HOSPITAL INFECTION 71.3 (2009), 223–
227.
[162] Elisabeth Rouits et al. “Pharmacokinetics of levetiracetam XR 500 mg tablets”.
In: EPILEPSY RESEARCH 84.2-3 (2009), 224–231.
[163] A. Rydzewska-Rosolowska, J. Borawski, and M. Mysliwiec. “High plasma endo-
statin level unaffected by low-molecular weight heparin in hemodialysis patients
- a preliminary report”. In: ADVANCES IN MEDICAL SCIENCES 54.2 (2009),
199–202.
[164] Alicja Rydzewska-Rosolowska, Jacek Borawski, and Michal Mysliwiec. “Hepato-
cyte Growth Factor/Activin A/Follistatin System Activation during Hemodialy-
sis with Different Low Molecular Weight Heparins”. In: RENAL FAILURE 31.9
(2009), 791–797.
[165] Stijn Schauvliege et al. “Comparison between lithium dilution and pulse contour
analysis techniques for cardiac output measurement in isoflurane anaesthetized
ponies: influence of different inotropic drugs”. In: VETERINARY ANAESTHE-
SIA AND ANALGESIA 36.3 (2009), 197–208.
[166] J. Schirra et al. “GLP-1 regulates gastroduodenal motility involving choliner-
gic pathways”. In: NEUROGASTROENTEROLOGY AND MOTILITY 21.6
(2009).
[167] K. J. Schjoedt et al. “Optimal dose of lisinopril for renoprotection in type 1
diabetic patients with diabetic nephropathy: a randomised crossover trial”. In:
DIABETOLOGIA 52.1 (2009), 46–49.
[168] Karin E. Schuetz et al. “Dairy cows prefer shade that offers greater protection
against solar radiation in summer: Shade use, behaviour, and body temperature”.
In: APPLIED ANIMAL BEHAVIOUR SCIENCE 116.1 (2009), 28–34.
99
[169] Jennifer Schweikart, Juergen Reimann, and Christiane Schoen. “Investigation of
niacin on parameters of metabolism in a physiologic dose: randomized, double-
blind clinical trial with three different dosages”. In: INTERNATIONAL JOUR-
NAL OF FOOD SCIENCES AND NUTRITION 60.Suppl. 5 (2009), 192–202.
[170] Lisa Kennedy Sheldon et al. “Nurse responsiveness to cancer patient expressions
of emotion”. In: PATIENT EDUCATION AND COUNSELING 76.1 (2009), 63–
70.
[171] Stephen B. Shrewsbury, Andrew P. Bosco, and Paul S. Uster. “Pharmacokinetics
of a novel submicron budesonide dispersion for nebulized delivery in asthma”. In:
INTERNATIONAL JOURNAL OF PHARMACEUTICS 365.1-2 (2009), 12–17.
[172] Frank Siebenhaar et al. “High-dose desloratadine decreases wheal volume and
improves cold provocation thresholds compared with standard-dose treatment in
patients with acquired cold urticaria: A randomized, placebo-controlled, crossover
study”. In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 123.3
(2009), 672–679.
[173] Stephen D. Silberstein et al. “Scheduled Short-Term Prevention With Frovatrip-
tan for Migraine Occurring Exclusively in Association With Menstruation”. In:
HEADACHE 49.9 (2009), 1283–1297.
[174] D. B. A. Silk et al. “Clinical trial: the effects of a trans-galactooligosaccharide
prebiotic on faecal microbiota and symptoms in irritable bowel syndrome”. In:
ALIMENTARY PHARMACOLOGY & THERAPEUTICS 29.5 (2009), 508–518.
[175] Hans-Uwe Simon and Bimal Malhotra. “The pharmacokinetic profile of fesotero-
dine: Similarities and differences to tolterodine”. In: SWISS MEDICAL WEEKLY
139.9-10 (2009), 146–151.
[176] A. M. G. A. de Smet et al. “Decontamination of the Digestive Tract and Orophar-
ynx in ICU Patients”. In: NEW ENGLAND JOURNAL OF MEDICINE 360.1
(2009), 20–31.
100
[177] Edmund J. S. Sonuga-Barke et al. “Adverse Reactions to Methylphenidate Treat-
ment for Attention-Deficit/Hyperactivity Disorder: Structure and Associations
with Clinical Characteristics and Symptom Control”. In: JOURNAL OF CHILD
AND ADOLESCENT PSYCHOPHARMACOLOGY 19.6 (2009), 683–690.
[178] Luigina Sorbara et al. “Multipurpose Disinfecting Solutions and Their Interac-
tions With a Silicone Hydrogel Lens”. In: EYE & CONTACT LENS-SCIENCE
AND CLINICAL PRACTICE 35.2 (2009), 92–97.
[179] Jan Hendrik Storre et al. “Clinical impact of leak compensation during non-
invasive ventilation”. In: RESPIRATORY MEDICINE 103.10 (2009), 1477–1483.
[180] Ana P. Teitelbaum et al. “Evaluation of the mechanical and chemical control of
dental biofilm in patients with Down syndrome”. In: COMMUNITY DENTISTRY
AND ORAL EPIDEMIOLOGY 37.5 (2009), 463–467.
[181] Pariyarath S. Thondre and C. Jeya K. Henry. “High-molecular-weight barley
beta-glucan in chapatis (unleavened Indian flatbread) lowers glycemic index”.
In: NUTRITION RESEARCH 29.7 (2009), 480–486.
[182] Rannveig Linda Thorisdottir et al. “A Comparison of Pharmacokinetics and
Pharmacodynamics of Biphasic Insulin Aspart 30, 50, 70 and Pure Insulin Aspart:
A Randomized, Quadruple Crossover Study”. In: BASIC & CLINICAL PHAR-
MACOLOGY & TOXICOLOGY 104.3 (2009), 216–221.
[183] Simon Thornley et al. “A single-blind, randomized, crossover trial of the effects
of a nicotine pouch on the relief of tobacco withdrawal symptoms and user satis-
faction”. In: NICOTINE & TOBACCO RESEARCH 11.6 (2009), 715–721.
[184] Marcello Tonelli et al. “Phosphate Removal With Several Thrice-Weekly Dialysis
Methods in Overweight Hemodialysis Patients”. In: AMERICAN JOURNAL OF
KIDNEY DISEASES 54.6 (2009), 1108–1115.
101
[185] Andre J. Tremblay et al. “Effects of ezetimibe and simvastatin on apolipoprotein
B metabolism in males with mixed hyperlipidemia”. In: JOURNAL OF LIPID
RESEARCH 50.7 (2009), 1463–1471.
[186] Jay K. Udani et al. “Lowering the glycemic index of white bread using a white
bean extract”. In: NUTRITION JOURNAL 8 (2009).
[187] Bernard Uzzan et al. “Efficacy of four insect repellents against mosquito bites: a
double-blind randomized placebo-controlled field study in Senegal”. In: FUNDA-
MENTAL & CLINICAL PHARMACOLOGY 23.5 (2009), 589–594.
[188] Frederic Vargas et al. “Helmet with specific settings versus facemask for nonin-
vasive ventilation”. In: CRITICAL CARE MEDICINE 37.6 (2009), 1921–1928.
[189] Niraj Vasisht et al. “Formulation Selection and Pharmacokinetic Comparison
of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate A
Randomized, Open-Label, Single-Dose, Crossover Study”. In: CLINICAL DRUG
INVESTIGATION 29.10 (2009), 647–654.
[190] Karthik Venkatakrishnan et al. “Effect of the CYP3A Inhibitor Ketoconazole on
the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With
Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized,
Two-Way Crossover Drug-Drug Interaction Study”. In: CLINICAL THERA-
PEUTICS 31.Part 2 Sp. Iss. SI (2009), 2444–2458.
[191] Joris C. Verster et al. “Novice drivers’ performance after different alcohol dosages
and placebo in the divided-attention steering simulator (DASS)”. In: PSYCHOPHAR-
MACOLOGY 204.1 (2009), 127–133.
[192] V. Vuksan et al. “Viscosity of fiber preloads affects food intake in adolescents”.
In: NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES 19.7
(2009), 498–503.
[193] Femke Waanders et al. “Effect of Renin-Angiotensin-Aidosterone System Inhi-
bition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury
102
Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc
Analysis of a Randomized Controlled Trial”. In: AMERICAN JOURNAL OF
KIDNEY DISEASES 53.1 (2009), 16–25.
[194] Emily C. Walvoord et al. “Inhaled Growth Hormone (GH) Compared with
Subcutaneous GH in Children with GH Deficiency: Pharmacokinetics, Pharma-
codynamics, and Safety”. In: JOURNAL OF CLINICAL ENDOCRINOLOGY
& METABOLISM 94.6 (2009), 2052–2059.
[195] Eva Wheatley and Kathleen A. Kennedy. “Cross-Over Trial of Treatment for
Bradycardia Attributed to Gastroesophageal Reflux in Preterm Infants”. In:
JOURNAL OF PEDIATRICS 155.4 (2009), 516–521.
[196] Barbara Wilhelm et al. “Lack of sedative effects after vespertine intake of oxazepam
as hypnotic in healthy volunteers”. In: PSYCHOPHARMACOLOGY 205.4 (2009),
679–688.
[197] Barth L. Wilsey et al. “Markers of abuse liability of short- vs long-acting opioids
in chronic pain patients: A randomized cross-over trial”. In: PHARMACOLOGY
BIOCHEMISTRY AND BEHAVIOR 94.1 (2009), 98–107.
[198] P. W. Wirtz et al. “Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the
Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-
Blind, Placebo-Controlled, Crossover Study”. In: CLINICAL PHARMACOL-
OGY & THERAPEUTICS 86.1 (2009), 44–48.
[199] Charles E. Wood, Thomas C. Register, and J. Mark Cline. “Transcriptional
profiles of progestogen effects in the postmenopausal breast”. In: BREAST CANCER
RESEARCH AND TREATMENT 114.2 (2009), 233–242.
[200] Jill Woods, Craig A. Woods, and Desmond Fonn. “Early Symptomatic Presbyopes-
What Correction Modality Works Best?” In: EYE & CONTACT LENS-SCIENCE
AND CLINICAL PRACTICE 35.5 (2009), 221–226.
103
[201] Daniel L. Worthley et al. “A human, double-blind, placebo-controlled, crossover
trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal,
inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer”. In:
AMERICAN JOURNAL OF CLINICAL NUTRITION 90.3 (2009), 578–586.
[202] Jing-li Wu et al. “Pharmacokinetics of Doxycycline Hydrochloride Administered
by Intravenous Infusion in Healthy Chinese Volunteers”. In: ARZNEIMITTEL-
FORSCHUNG-DRUG RESEARCH 59.1 (2009), 49–54.
[203] Jun Yang, Rui Hai Liu, and Linna Halim. “Antioxidant and antiproliferative
activities of common edible nut seeds”. In: LWT-FOOD SCIENCE AND TECH-
NOLOGY 42.1 (2009), 1–8.
[204] Ruoqi Zhang et al. “Pharmacokinetics and Tolerability of Multiple-Dose Rosu-
vastatin: An Open-Label, Randomized-Sequence, Three-Way Crossover Trial in
Healthy Chinese Volunteers”. In: CURRENT THERAPEUTIC RESEARCH-
CLINICAL AND EXPERIMENTAL 70.5 (2009), 392–404.
104
